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1 Summary 
Canine mammary tumours (CMTs) are suggested as good model for human breast 
cancer to better understand tumour biology and discover new biomarkers. Cancer-
associated stroma (CAS) occupies a central role in cancer development and 
progression, and presents an interesting diagnostic and therapeutic target for both 
humans and dogs. However, in contrast to human cancer, CAS in CMTs remains 
largely uncharacterised. To analyse CAS from CMTs, we established isolation of 
CAS and matched normal stroma from formalin-fixed paraffin embedded (FFPE) 
tissue samples by laser-capture microdissection (LCM), and analysed gene 
expression by quantitative real-time PCR (RT-qPCR) and next-generation RNA 
sequencing (RNAseq). Using this setup, we investigated the expression of known 
human CAS markers in canine CAS. Furthermore, to identify possible drivers of 
tumour progression, we analysed CAS and normal stroma from 15 metastatic and 16 
non-metastatic CMTs. Our findings show that i) CAS in CMTs undergoes strong 
reprogramming towards a tumour supportive function comparable with human CAS, 
and ii) CAS from metastatic tumours clearly differs from non-metastatic tumours, 
potentially enabling the identification of novel biomarkers and therapeutic targets for 
metastatic disease. Among other targets, we identified MMP11 as a possible new 
biomarker for metastatic CMTs. In summary, our data demonstrates the usability of 
FFPE tissue for RNAseq, and supports the use of the dog as a model of human 
breast cancer. 
 
Keywords: canine mammary tumour, breast cancer, CAS, FFPE, LCM, metastases, 
MMP11 
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2 Zusammenfassung 
Mammakarzinome des Hundes (CMKs) werden als gutes Modell für die Erforschung 
von Brustkrebs diskutiert. Die zentrale Rolle des Tumorstromas (TS) in der 
Tumorbiologie macht das TS für Diagnostik und Therapie bei Mensch und Hund 
höchst interessant. Im Gegensatz zum Menschen ist jedoch das TS in CMKs 
grösstenteils unerforscht. Um TS von CMKs detailliert zu untersuchen, haben wir die 
Isolation von TS und normalem Stroma aus Formalin-fixierten und in Paraffin-
eingebetteten (FFPE) Proben mittels Laser-capture microdissection (LCM) etabliert, 
und die Genexpression mittels quantitativer PCR (RT-qPCR) oder RNA 
Sequenzierung (RNAseq) analysiert. Mittels dieser Technik haben wir die Expression 
von humanen TS-Markern im TS des Hundes ermittelt. Des Weiteren, um mögliche 
Treiber der Tumorprogression zu identifizieren, haben wir TS und normales Stroma 
von 15 metastatischen und 16 nicht-metastatischen CMKs erforscht. Unsere 
Ergebnisse zeigen, dass i) TS von CMKs, ähnlich dem humanen TS, 
umprogrammiert und eine tumorunterstützende Funktion übernimmt, und ii) TS von 
metastatischen Tumoren sich klar von nicht-metastatischen unterscheidet, was zur 
Identifikation neuer Biomarker und therapeutischer Ansatzpunkte für 
metastasierenden Krebs führen kann. Neben weiteren Kandidaten haben wir MMP11 
als möglichen neuen Biomarker für CMKs identifiziert. Zusammenfassend beweisen 
unsere Daten die Verwendbarkeit von FFPE Gewebe für RNAseq und unterstützen 
die Verwendung des Hundes als Modell für Brustkrebs. 
 
Schlüsselwörter: Mammakarzinom des Hundes, Brustkrebs, CAS, FFPE, LCM, 
Metastasen, MMP11 
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3 Abbreviations 
ACTA2/αSMA alpha smooth muscle actin 
ASCs   adipose tissue-derived stem cells 
AVCs   angiogenic vascular cells 
CAFs   cancer-associated fibroblasts 
CAS   cancer-associated stroma 
CMTs   canine mammary tumours 
CAV1   caveolin 1 
COL1A1  collagen type I alpha 1 chain 
COL14A1  collagen type XIV alpha 1 chain 
CXCL12  C-X-C-motif chemokine ligand 12 
DER-2  dog epidermal growth factor receptor-2 
DIO3   deiodinase 3 
E1   elution 1 
ECM   extracellular matrix 
EMT   epithelial-to-mesenchymal transition 
ER   oestrogen receptor 
FAP   fibroblast activation protein 
FFPE   formalin-fixed paraffin embedded 
FGF2   fibroblast growth factor 2 
GnRH   gonadotropin-releasing hormone 
HER-2  human epidermal growth factor receptor-2 
HIF-1   hypoxia-inducible factor 1 
IICs   infiltrating immune cells 
IL6   interleukin 6 
LCM   laser-capture microdissection 
MMP2  matrix metalloproteinase 2 
MMP11  matrix metalloproteinase 11 
MSCs   mesenchymal stem cells 
NK cells  natural killer cells 
NST   invasive carcinoma of no special type 
PCOLCE2  procollagen C-endopeptidase enhancer 2 
PDGFRB  platelet derived growth factor receptor beta 
PR   progesterone receptor 
RIN   RNA integrity number 
RNAseq  RNA sequencing 
RT-qPCR  quantitative real-time PCR 
SEMA3G  semaphorin 3G 
SFRP1  secreted frizzled related protein 1 
SLIT2   slit guidance ligand 2 
TAMs   tumour-associated macrophages 
TCGA   The Cancer Genome Atlas 
TGFβ   transforming growth factor beta 
TGFB2  transforming growth factor beta 2 
TGFBR3  transforming growth factor receptor 3 
Tregs   regulatory T-cells 
VIT   vitrin 
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4 Introduction 
4.1 Breast cancer as a challenge for the global healthcare system 
The term “cancer” encompasses a large group of complex diseases that is 
responsible for an estimated 9.6 million deaths in 2018 all over the world. This makes 
cancer the second leading cause of death after cardiovascular diseases, both in 
Europe and worldwide [1-3]. The formation of cancer is a multistage process starting 
with the transformation of normal cells into tumour cells, which start to divide 
uncontrollably and give rise to a primary tumour. Moreover, some of these cells can 
overcome their physiological barriers, invade the surrounding tissues and even 
spread to distant organs. This final stage of cancer, known as metastasis, represents 
the main reason for cancer-related deaths [1]. 
In Switzerland over 40’000 people are diagnosed with cancer each year, with a rising 
tendency due to the increasing average age of the population. In contrast to this, the 
mortality for most cancer types is decreasing thanks to a good healthcare system, the 
continuous expansion of the knowledge on cancer, and the implementation of 
screening methods and more efficient treatments. Nevertheless, over 16’000 cancer 
patients die each year in Switzerland [4]. Breast cancer is the most frequent cancer 
type in women both worldwide and in Switzerland [4-6]. In the period from 2008 to 
2012 in Switzerland, over 5700 patients were newly diagnosed with breast cancer, 
and 1400 patients died of breast cancer each year. Currently, the risk for Swiss 
women to develop breast cancer over a lifetime accounts for 12.7% (13 of 100 
women) [4]. These high numbers clearly demonstrate that, despite significant 
advances in treating breast cancer over the last decades, there is still a large need 
for improved understanding of the disease to develop better therapeutic approaches, 
especially so for metastatic breast cancer. 
4.2 The importance of the cancer-associated stroma (CAS) in 
cancer biology 
Tumour cells have been in the focus of attention of cancer research for many 
decades, and the accumulation of genetic and epigenetic changes in these cells 
were classically considered as the main driving force for tumour development [7-10]. 
However, more recent results show that tumorigenesis is not a cell-autonomous 
process, but results from a reciprocal interaction between the tumour cells and their 
surrounding tissue. This surrounding tissue is also known as cancer-associated 
stroma (CAS) or tumour stroma [2, 7-9, 11-14]. The CAS consists of a mixture of 
various stromal cells and extracellular matrix (ECM) that have been shown to support 
growth and survival of the tumour cells [7, 8, 11, 12, 14]. The cells in CAS can be 
divided into three main cell types: i) angiogenic vascular cells (AVCs) including 
endothelial cells and pericytes, ii) cancer-associated fibroblastic cells (CAFs) 
comprising activated tissue resident fibroblasts and myofibroblasts, mesenchymal 
stem cells (MSCs), and activated adipocytes, and iii) infiltrating immune cells (IICs), 
such as lymphocytes, neutrophils and tumour-associated macrophages (TAMs) [11]. 
Under physiological conditions, epithelial and stromal interaction is essential for 
normal tissue formation and maintenance. The stroma maintains epithelial polarity 
and serves as an important barrier to prevent neoplastic transformation and 
uncontrollable cell proliferation. However, the presence of cancerous cells leads to 
reprogramming of the stromal compartment towards a tumour supportive function 
Introduction 
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[11, 13, 14]. This reprogramming of the stroma through tumour cells is achieved 
through a multitude of mechanisms, including exchange of signals through direct cell-
cell contact, secretion of soluble factors like growth factors, cytokines, hormones as 
well as metabolites, secretion of exosomes containing miRNA, RNA and proteins, 
and others. All these mechanisms lead to gene expression changes in stromal cells 
that promote a tumour-cell supportive phenotype [7, 12, 14]. All of the CAS resident 
cells have been shown to significantly influence and contribute to the hallmarks of 
cancer [11]. Indeed, CAS has been shown to influence cancer initiation, growth and 
metastasis, and even to drive the development of resistance towards cancer therapy 
[7, 9, 11, 12, 14]. The different mechanisms by which CAS influences tumour growth 
and progression in general, and breast cancer in particular, is outlined in more detail 
in the following sections. 
4.2.1 Influence of CAS on tumour growth 
One of the major characteristics of cancer is the uncontrolled growth of tumour cells. 
This is partly a cell-intrinsic characteristic, but can also be strongly influenced through 
different cell types present in CAS. 
CAFs represent a central component of the CAS in breast cancer, as they are 
responsible for building, maintaining and altering the structural framework of the 
tissue by secretion of ECM components [2, 7-9, 11, 12, 14]. CAFs derive from 
various sources such as normal fibroblasts, bone marrow-derived MSCs, adipose 
tissue-derived stem cells (ASCs), smooth muscle cells, and endothelial cells [2, 7-9, 
11, 12]. These cells can be identified through a combination of different markers, 
including fibroblast activation protein (FAP), alpha smooth muscle actin (αSMA), 
tenascin C (TNC), and loss of markers like caveolin 1 (CAV1) and phosphatase and 
tensin homolog (PTEN) [7-9, 12]. CAFs have been shown to strongly impact on 
tumour growth and progression through the secretion of various growth factors 
including hepatocyte growth factor (HGF), epidermal growth factor (EGF), insulin like 
growth factor 1 and 2 (IGF1/2), platelet-derived growth factor (PDGF), transforming 
growth factor beta (TGFβ), basic fibroblast growth factor (bFGF) and vascular 
endothelial growth factor (VEGF), and many more. Furthermore, cytokines like 
interleukin 6 (IL6) and chemokines such as C-X-C-motif chemokine ligand 12 
(CXCL12) are released by CAFs to promote epithelial cell growth [7-12, 14]. In breast 
cancer, these factors have also been shown to influence tumour growth indirectly by 
increasing tissue estradiol (E2) levels, which in turn results in enhanced proliferation 
of breast cancer cells [9]. Additionally, CAFs disrupt normal tissue structure by 
secretion of proteases like matrix metalloproteinases (MMPs) that dissolve epithelial 
cell-cell contacts, thus circumventing growth suppression pathways through contact 
inhibition [2, 8, 11]. 
Aside from CAFs, also IICs are known to contribute to tumour growth by secretion of 
growth factors (TGFβ, EGF, FGF), proteases and cytokines like C-C motif chemokine 
ligand 2 (CCL2) or interleukin (IL10) [11, 14]. Furthermore, IICs are involved in 
suppressing cell death pathways by binding to disconnected epithelial cancer cells, 
thus allowing them to survive in the new microenvironment [11]. 
To grow at an increased rate, tumour cells do not only depend on growth promoting 
signalling pathways, but also on an appropriate supply with adequate levels of 
oxygen and energy-rich metabolites. To this end, they trigger angiogenesis through a 
variety of proangiogenic factors including VEGF, CXCL12, interleukin 8/ C-X-C-motif 
chemokine ligand 8 (IL8/CXCL8), platelet derived growth factor receptor beta 
(PDGFRβ), TGFβ, MPPs, and FGF that are secreted by CAFs, IICs, pericytes as well 
as cancer cells themselves [8, 9, 11, 12]. Angiogenesis does not only play an 
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important role in primary tumour growth, but also supports invasion of the 
surrounding tissue and metastasis to distant organs [8, 11, 12]. To increase their 
supply with energy-rich metabolites, tumour cells have been shown to induce 
metabolic reprogramming in CAFs by releasing reactive oxygen species. This drives 
CAFs towards aerobic glycolysis, which results in the secretion of lactate and 
pyruvate that is taken up by the tumour cells to fuel their energetic demands [8, 10, 
11]. 
 
Another key feature of malignant cancer cells is their ability to develop distant 
metastases, which are responsible for most cancer deaths [1, 8, 15]. For a tumour to 
form metastases, both tumour cells and the neighbouring CAS have to undergo 
multiple changes to enable this complex process. The first step in this process is for 
cancer cells to start invading the local tissue, and gain access to blood or lymph 
vessels (intravasation). Once in the circulation, cancer cells have to survive in the 
vasculature and exit from the vessels (extravasation) at the target organ, where they 
need to restart growing in order to form new colonies of tumour cells (colonisation) [8, 
9, 14, 15]. The ability to degrade the ECM, an enhanced motility as well as 
undergoing epithelial-to-mesenchymal transition (EMT) have been shown to be 
important for tumour cells to invade their cellular surroundings and enter the vascular 
system [8, 9, 15]. Cancer cells do not achieve all these milestones on their own, but 
are strongly supported by the surrounding stroma in many of these aspects. 
Interestingly, the genes that are deregulated the most in CAS are related to ECM 
remodelling [16]. CAFs and IICs alter the ECM by secreting digestive enzymes like 
MMP2, MMP9, MMP11, serine proteases like urokinase-type plasminogen activator 
(uPA), and cysteine proteases influencing ECM components like collagen, fibronectin 
and tenascin C, thus leading to degradation and disorganisation of the ECM [2, 7, 8, 
11, 14, 17]. The ECM alteration is reflected in the clinical presentation of breast 
cancer patients, where increased collagen deposition, collagen crosslinking and 
tissue density can be observed by palpation and diagnostic imaging [14, 16, 18]. For 
successful intravasation, tumour cells need to acquire an invasive phenotype, which 
can be triggered through expression of TGFβ by CAFs as well as IL6 or tumour 
necrosis factor alpha (TNFα) that are secreted by IICs [8, 11, 19]. Furthermore, 
looser tight junctions and rarer coverage through pericytes can be found around 
VEGF induced tumour vasculature, both of which facilitates cancer cell intra- and 
extravasation at the metastatic site [11]. To survive in circulation tumour cells do 
normally not spread as single cells, but instead travel together with fibroblasts from 
the primary mass. Finally, it has been shown that the pre-metastatic niche gets 
prepared by bone marrow-derived cells recruited by chemokines and cytokines 
released from the primary tumour, thus allowing the tumour cells to preferentially 
invade this niche and grow more easily [8, 14]. Taken together, the different 
components of CAS have been shown to influence all steps of cancer growth, 
development, invasion and metastasis directly as well as indirectly through a variety 
of mechanisms. 
4.2.2 The role of CAS in cancer-associated inflammation and suppression of 
the immune system 
Cancer-associated inflammation is another important component of the tumour 
stroma. It is mediated through different immune cells such as lymphocytes, 
neutrophils, eosinophils, mast cells, dendritic cells and macrophages. Presence of 
these IICs is usually associated with higher tumour grade, enhanced necrosis, loss of 
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hormone receptors and worse prognosis [9, 12, 14, 20]. Normally, IICs are able to 
destroy cancer cells, as these can be recognised as non-physiological cells within the 
tissue. The paradoxically worsened prognosis in the presence of immune cells is 
caused by a reprogramming of the IICs through the tumour cells towards a cancer 
cell tolerant phenotype. As a result, instead of fighting against tumour cells, the 
reprogrammed IICs actually promote tumour growth, angiogenesis, and metastasis 
[8, 9, 21]. Among the major players that exert pro-tumorigenic properties are tumour 
associated macrophages (TAMs). They originate from blood monocytes which are 
recruited to the tumour via cytokines including CCL2, IL6, TNFα and CXCL12 that 
are expressed by both tumour and stromal cells [8, 12, 14]. Most TAMs show a so-
called proinflammatory or M2 phenotype, and secrete various cytokines such as IL4, 
IL10, CCL2, CCL17, CCL22, TGFβ as well as VEGF, PDGF, FGF, MMPs, and uPA 
which are involved in tissue remodelling, angiogenesis, tissue and blood vessel 
invasion and immunosuppression [9-12, 14, 17, 20]. 
Another group of IICs are lymphocytes, mostly regulatory T-cells (Treg), CD8+ T-
cells, CD4+ helper cells and natural killer (NK) cells. Tregs normally protect the body 
against autoimmune responses. However, in the tumour tissue they enable the 
cancer cells to evade the immune system by supressing various immune cells, 
including the main effector cells CD8+ T-cells and NK cells that mediate elimination 
of tumour cells [11, 14, 21]. IICs express a molecule called programmed cell death 1 
(PD-1), which inhibits inappropriate T-cell function in normal tissues. In cancer 
however, PD-1 binds its ligand PD-L1 that is expressed by tumour cells, which leads 
to inactivation of T-cells and thus the establishment of an immunosuppressive 
microenvironment [14, 22]. Dendritic cells in CAS have also been shown to exhibit an 
altered function, as most of them remain in an immature state unable to inhibit 
tumour growth, but instead promote angiogenesis through secretion of proangiogenic 
factors [14, 21]. Finally, not only IICs themselves, but also CAFs and ACV influence 
cancer-associated inflammation by inhibiting the T-cell function via TGF-β and 
impeding T-cell extravasation [8, 11]. 
In summary, tumour cells are not self-sufficient and heavily depend on the 
surrounding stroma. CAS influences growth and metastasis of tumour cells through 
complex interactions of a multitude of direct and indirect mechanisms deriving from 
various cellular sources. Thus, the interplay between tumour cells and CAS is 
emerging as centrally relevant for the growth and development of cancer cells. 
However, even though the details of this interplay between tumour cells and 
components of the CAS are slowly being unveiled, we are still far from a complete 
understanding of the mechanisms involved in this dialogue. A better understanding of 
the factors involved and their effects has the potential to uncover novel therapeutic 
strategies to inhibit both cancer cell growth and metastasis. 
4.3 Spontaneous tumours in dogs as a model for human cancer 
A plethora of in vitro and in vivo models have been used over the last century to 
gather knowledge about cancer biology. While these models have been highly 
informative in many aspects, there are inherent limits in using such models, as they 
cannot fully replicate the conditions of real, spontaneously developing patient 
tumours [23-27]. A rather novel field of research, referred to as comparative 
oncology, aims at opening up new possibilities by shifting the focus from classical 
rodent models to other animals including dogs. This additional perspective is seen as 
a chance to better understand complex diseases like cancer, as the comparison of 
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tumour development and risk factors across species provides the opportunity to 
discover basic mechanisms of tumorigenesis [23, 24, 28]. 
The domestic dog is considered one of the best examples for comparative oncology 
as it shares many similarities with humans. First of all, dogs have about the same 
number of genes as humans and share evolutionarily conserved alterations in the 
genome [23, 24, 26, 28-30]. Cancer in both species develops spontaneously, and 
manifests in a similar clinical presentation, pathophysiology, and histology. As such, 
development of spontaneous tumours in dogs has strong parallels with the natural 
progression of cancer development in humans, and is considered a better proxy of 
tumour biology than animal models with induced tumorigenesis. The higher life 
expectancy compared to rodent models and the similar environmental factors that 
dogs and humans are exposed to, combined with the fact that dogs often receive a 
high level of healthcare further strengthens the value of comparatively analysing 
canine and human cancers [1, 23, 24, 25, 31]. Furthermore, canine tumours have 
been shown to harbour genetic aberrations in the same genes as the corresponding 
human tumour types, including for instance BRCA1 and BRCA2 mutations which 
lead to an enhanced risk of hereditary breast and ovarian cancer in humans [23, 25, 
30, 32, 33]. Additionally, certain breeds of dogs carry genetic predispositions for 
certain cancer types as a result of inbreeding and high degrees of consanguinity, 
thus facilitating the discovery of risk alleles responsible for the disease [23-25, 28, 30, 
34]. Altogether, these insights emphasise the potential of the dog as models for 
human cancer and offers the possibility to overcome limits of xenograft and 
genetically engineered rodent models leading to improved understanding of tumour 
biology and facilitating biomarker discovery [23-25, 27, 28]. 
4.4 Comparing canine mammary tumours and human breast 
cancer 
Among many different cancer types, canine mammary tumours (CMTs) are regarded 
as good models for human mammary carcinomas [35, 38]. The age of onset is 
comparable in both women and bitches when converting dog years into human 
years. The incidence of CMTs starts to increase after the age of 6 (humans 40 years) 
and peaks between 8 to 14 years (humans 50 to 70 years) [4, 26, 36, 38]. 
Furthermore, it is the most frequent cancer diagnosed both among female dogs as 
well as women suffering from cancer [25, 32, 35]. A retrospective study on tumours in 
dogs in Switzerland between 1955 and 2008 found that 20.53% of all canine tumours 
were located in the mammary gland [37]. On a global level, CMTs occur in more than 
40% of female dogs and show and annual incidence rate varying between 192 to 
205/100’000 dogs, which is even higher than incidence rates of 125/100’000 women 
in the United Stated and 144/100’000 women in Switzerland [4, 25, 34, 36, 38]. 
Interestingly, the United States have lower numbers for CMTs than other countries 
like Sweden, presumably because dogs get neutered at an early age and receive 
less gestagen preparations for heat prevention. Particularly neutering before the first 
oestrus minimizes the risk of CMTs to 0.5% compared to intact bitches, rising to 8% 
when neutered after the first oestrus, and rising to 26% when neutered after the 
second oestrus. However, no protective effects of neutering after the second oestrus 
has been found in dogs older than 2.5 years [34, 36]. The protective effect of 
neutering is indicative of a significant contribution of sex hormones to the 
development of CMTs. Under physiological conditions and in early stages of human 
and canine breast cancer development, sex hormones, such as oestrogen and 
progesterone, stimulate mammary tissue growth through specific binding of 
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hormones to their cognate receptors oestrogen receptor (ER) and progesterone 
receptor (PR). This effect can also be induced by synthetic gestagen used for oestrus 
preventions. Especially progesterone derivates have been shown to promote 
increased growth hormone production in the mammary gland, thus leading to IGF1 
secretion, which stimulates cell proliferation. However, during disease progression, 
expression of hormone receptors can be lost, resulting in hormone-independent 
proliferation [34-36, 38, 39]. 
 
The anatomy of the normal mammary gland is similar in dogs and women. The 
alveoli and ducts of the mammary gland consist of luminal epithelial cells lined by 
myoepithelial cells and are separated from the surrounding connective tissue by the 
basement membrane [10, 36]. In both species tumorigenesis is seen as a dynamic 
process starting with benign hyperplastic lesions potentially turning into carcinoma in 
situ and finally becoming invasive, a stage which is marked by the disruption of the 
basement membrane [35, 40-42]. 
Histological classification of human breast cancer consists of more than 20 subtypes 
from which the invasive carcinoma of no special type (NST) is diagnosed most 
frequently, accounting for 40% to 75% of diagnoses [4, 32]. The wide range of NST 
cases is usually explained by improperly applied inclusion criteria leading to the 
inclusion of many specific subtypes in this type. This is not surprising, as NST 
morphology is very variable and includes tumour cells arranged in clusters, 
trabeculae and cords or some that even show a solid or syncytial tissue structure [32, 
43]. Thus, relevance of histological classification is limited, not least because many 
studies show differences between different NST in clinics and treatment response 
[44]. 
In canines, most malignant mammary tumours arise from epithelial cells and are 
either defined as simple carcinomas or, in cases where myoepithelial cell proliferation 
can be simultaneously observed, complex carcinomas [34, 36, 45]. Canine simple 
carcinomas strongly resemble human breast cancer both histologically and at the 
molecular level, whereas complex carcinomas are rarely diagnosed in women [25, 
46, 47]. Histological classification of CMTs slightly differs from the human 
classification and has been modified stepwise over the past 40 years. The WHO 
histologic classification from 1999 defined simple carcinoma subtypes for the first 
time including the tubulopapillary carcinoma, solid carcinoma and anaplastic 
carcinoma. In 2010 a new classification was proposed by Goldschmidt et al dividing 
simple carcinomas into a tubular, tubulopapillary, cystic-papillary and cribriform 
subtype. Moreover, solid and anaplastic carcinomas were specified as independent 
types, and new tumour types like the comedocarcinoma were added [45]. 
Nevertheless, the clinical relevance of the exact histologic classification into subtypes 
remains questionable [48]. 
Tumour grading is an additional feature that is assed in histological examination of 
invasive human breast carcinomas, and which has been adapted to invasive canine 
carcinomas. On the basis of tubule formation, nuclear pleomorphism and mitotic 
counts, carcinomas can be divided into three grades. Grade I tumours are well 
differentiated, grade II tumours are moderately differentiated and grade III tumours 
are poorly differentiated. Grade III is associated with worse survival in both species, 
and accordingly lymphatic invasion as well as lymph node metastasis is spotted more 
frequently in these cases [32, 45, 49-51]. In dogs, reports have associated different 
grades with different histological subtypes, showing most tubular and tubulopapillary 
carcinomas being well differentiated, whereas solid, comedocarcinoma and 
anaplastic carcinoma exhibited higher grades [49, 51, 52]. 
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Besides clinical factors like tumour size, lymph node involvement, clinical stage, 
histological tumour type and grade, molecular subtypes (named luminal A, luminal B, 
HER2-enriched and basal-like) have been found to be prognostic in both canine and 
human breast cancer [30, 32, 34, 38, 49, 51-54]. The luminal A subtype is 
characterised by ER and/or PR expression, well differentiated cells and low 
proliferation rates [38, 44, 55]. Luminal B tumours also express ER and/or PR but 
have a higher proliferation rate and grade, with worse prognosis than luminal A [44]. 
Human epidermal growth factor receptor-2 (HER-2) enriched cancers are associated 
with high tumour grades and result from amplification of the erb-b2 receptor tyrosine 
kinase 2 (ERBB2) gene [44]. In dogs, contradictory results of HER-2 expression in 
CMTs have been reported. However, a homologue of HER-2 has been found in 
CMTs, termed dog epidermal growth factor receptor-2 (DER-2), showing similar 
biological effects [30, 34, 47, 53, 56-58]. The basal-like subtypes express basal cell 
markers and show no ER, PR or HER-2 expression. Therefore, this phenotype is also 
known as triple negative breast cancer associated with high malignancy, poor 
differentiation, enhanced proliferation and lymphatic invasion resulting in shorter 
overall survival [30, 38, 44, 52, 55]. To conclude, expression of hormone receptors 
and HER-2 in CMTs has been associated with similar clinics in human breast cancer. 
This suggests that they can serve as biomarkers in dogs, and also points out an 
additional commonality between the two species [38, 55]. However, assessment of 
molecular subtypes is still limited to research purposes and not routinely applied in 
CMT diagnosis [34, 54]. 
Taken together, the similarities between CMTs and human breast cancer indicate 
comparable tumour biology, and studying CMTs offers the opportunity to find novel 
biomarkers not only for dogs but also humans. Comparing the same disease in two 
different species additionally helps differentiating the molecular ‘driver’ of the disease 
from mere ‘passengers’, as the central drivers should be conserved between species. 
Finally, clinical trials in dogs can be conducted in a shorter period than human 
studies, due to a reduced lifespan and associated earlier manifestation of cancer 
[24]. 
4.5 Largely uncharted territory: cancer-associated stroma in 
canine mammary tumours 
Studies investigating human cancer cells and their TME have started to reveal the 
importance of CAS in cancer initiation and progression, and emphasise the potential 
of targeting CAS in cancer therapy. One of the currently most promising strategies is 
immunotherapy, used as additional treatment modality to complement chemotherapy, 
radiotherapy and/or surgery [59, 60]. As CAS plays such a pivotal role in the biology 
of human cancer, it very likely also strongly influences tumour growth and 
development in dogs. However, to date, data regarding CAS in canine cancers is 
very rare. Most studies investigating CMTs have analysed the whole tumour tissue by 
sequencing or microarray analysis. In cases where CAS was looked at specifically, 
only single markers were analysed using immunohistochemistry [25, 27, 38, 61, 62]. 
 
A well-known CAF marker αSMA and the ECM molecule TNC were found to be 
expressed in myofibroblasts within CAS of canine simple mammary carcinomas. The 
presence of stromal myofibroblasts and the expression of TNC were associated with 
higher histological grade, vessel invasion, metastasis, and worse prognosis, 
correlating with findings in human breast cancer [63].  
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Similarly, the role of inflammatory cells and their gene expression signature in the 
canine CAS is still understudied. Very few studies have been conducted in CMTs 
considering the number of TAMs, T and B-cells in the tumour bed and their influence 
on clinical outcome. Most studies demonstrated that the amount of lICs is higher in 
malignant and metastasizing tumours and also Treg were shown to be associated 
with high histological grade and metastasis [10]. There is not much published data 
regarding the gene expression profile of IICs in CMTs. One immunohistochemistry 
study shows an increased expression of IL1 and TNFα in the stroma as well as in 
epithelial cells, associated with tumour malignancy and metastasis [64]. A second 
study investigating TAMs found upregulated genes like CXCL10 and Wnt ligands, 
both of which are suggested to be involved in angiogenesis [65].  
The most thoroughly investigated enzymes regarding invasion in CMTs are MMP2, 
MMP9, and uPA [10]. These factors were shown to be expressed by both CAFs and 
tumour cells [10, 66, 67]. MMP2 up-regulation was shown to be associated with 
tumour malignancy including higher tumour stage [66, 67]. MMP9 expression was 
higher in malignant tumours compared to benign neoplasms and related with high 
histologic grade, invasion, metastasis and shorter survival times [66, 68]. Expression 
of uPA was also associated with malignant behaviour including increase in tumour 
size, higher histological grade, proliferation, invasive growth, metastasis in lymph 
nodes and distant organs as well as reduced overall survival and disease-free 
survival [10, 69]. In a multivariable survival study MMP9 and uPA presented better 
prognostic factors than classic histological parameters like tumour size and grade. 
Therefore, they are discussed as potential prognostic and therapeutic targets in 
CMTs [10, 70].  
Other main biomarkers analysed in CMT by immunohistochemistry are VEGF and 
vascular endothelial growth factor receptor (VEGFR2). In CMTs VEGF was shown to 
be expressed in endothelial cells, TAMs and tumour cells with higher expression 
levels in malignant, high grade, and necrotic tumours leading to endothelial cell 
proliferation [71-73]. Expression of VEGFR2, shown to be expressed in endothelial 
cells, was also associated with malignancy and metastasis to the lungs. Highest 
VEGFR2 levels were detected in comedocarcinomas suggesting it may play an 
important role in this subtype [71, 74]. 
 
While adding important information to the field of CAS in canine tumours, all these 
reports have only investigated a very limited number of targets, and no unbiased 
analyses have been performed to investigate gene expression patterns in CAS from 
CMTs. Thus, it remains largely unknown whether CAS in canine and human breast 
cancer are comparable, and what the molecular similarities and differences are. A 
better understanding of the biology of CAS in CMTs is imperative to understand 
whether canine breast cancer really is comparable to the human disease in all of its 
aspects, and to understand how CAS influences growth and progression of CMTs. 
  
Introduction 
 
16 
4.6 Aim of this thesis 
Given the central role of CAS for the biology of human breast cancer, it is also very 
likely to be a very important component in the growth and development of CMTs. To 
date however, CAS in CMTs remains practically uncharacterised, and it is unclear to 
what extent CAS from canine and human tumours can be compared. An improved 
understanding of the canine CAS will serve to validate CMTs as model for the human 
disease, and comparative studies with human breast cancer have the potential to 
identify key drivers of tumour growth and metastasis. 
To better understand the mechanisms involved in CAS formation of CMTs and be 
able to identify commonalities and differences between canine and human CAS, we 
set out to analyse the gene expression of CAS from canine simple mammary 
carcinomas. Specifically, the aims of my thesis were the following: 
 
1) Establish a protocol to analyse the expression of selected CAS markers for 
human breast cancer in CAS from canine mammary carcinomas. 
2) Develop a protocol to analyse CAS and normal stroma from FFPE tissues by 
next-generation RNA sequencing (RNAseq). 
3) Analyse CAS and normal stroma from non-metastatic versus metastatic 
canine mammary carcinomas to investigate the changes in canine CAS and 
identify differentially regulated genes that could potentially be used as 
prognostic or therapeutic targets. 
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5 Materials and methods 
A large part of the materials and methods that were used have already been 
described in detail in my master thesis [75] as well as the two studies that are 
included in this thesis of which I am first and shared first author, namely “Analysis of 
gene expression signatures in cancer-associated stroma from canine mammary 
tumours’’[76] and “An optimised protocol for isolation of RNA from small sections of 
laser-capture microdissected FFPE tissue amenable for next-generation sequencing” 
[77]. In the following section the entire procedure is outlined in brief to give a 
complete overview of all materials and methods used. 
5.1 Selection criteria for tissue specimens 
Twenty-one canine simple mammary carcinomas were provided by the Institute of 
Veterinary Pathology of the Vetsuisse Faculty Zurich. These are cases that were 
either from the Small Animal Hospital of Zurich or external cases sent in by Swiss 
veterinarians. Additional ten cases were provided by Prof. R. Klopfleisch from the 
Institute of Veterinary Pathology of the Freie Universität Berlin and have already been 
part of a previously published study [61]. These cases had slight differences in 
fixation and histological classification criteria, the details of which can be found in [61] 
and further below. All samples were formalin-fixed, paraffin embedded (FFPE) and 
selected by a pathologist. The criteria for inclusion in this study were as follows: 
female dogs, simple mammary carcinomas, histological tumour grade I-III, sufficient 
tumour and normal stroma for isolation, and available information on lymph nodes 
regarding metastases. 
The decision to include simple mammary carcinoma was based on its similarity to 
human breast cancer regarding histology and molecular pattern [25, 46, 75, 78]. 
Selection criteria of the modified WHO classification and the histologic grading 
system from Clemente et al were applied [45, 51, 79]. Following simple carcinoma 
subtypes were included: tubular, tubulopapillary, cribriform, cystic-papillary, solid and 
comedocarcinoma [45]. The anaplastic subtype was excluded as the highly invasive 
growth pattern with scattered epithelial cells impeded the selective extraction of 
stromal cells. Furthermore, instead of a primary mass, the tumour cells of anaplastic 
carcinomas were often found in lymphatic vessels, which made it difficult to define 
the appropriate distance for isolating normal stroma. The selection criterion for 
metastatic tumours was presence of metastases in histological sections of regional 
lymph nodes found by microscopic examination, whereas non-metastatic tumours 
were defined by regional lymph nodes free of metastases. 
The cases were reviewed by a board-certified veterinary pathologist using routinely 
stained H & E slides cut at 2 μm. If no clear identification was achieved, the cases 
were discussed with colleagues of the institute. When difficulties in the distinction 
between simple and complex carcinomas appeared, immunohistochemistry using the 
myoepithelial cell marker p63 (1:50, ab735, Abcam) was conducted to detect 
myoepithelial cell proliferation. The slides were stained according to a standard 
protocol established at the Institute of Veterinary Pathology, University of Zürich 
(available upon request). 
5.2 Tissue preparation for laser-capture microdissection (LCM) 
Tissue specimens were fixed in 10% neutral buffered formalin (Zürich), or 4% neutral 
buffered formalin (Berlin), and subsequently embedded in paraffin. The microtome 
HM 360 (ThermoFisher Scientific) was used to cut 10 µm tissue sections. The water 
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was treated with DEPC and the blade was cleaned with RNase away™ (Ambion) to 
avoid mRNA degradation during cutting. After cutting the sections were mounted on 
PEN Membrane Glass Slides (Applied Biosystems™) and dried at room temperature 
overnight. To enable identification of stroma, tissue sections were stained with Cresyl 
violet according to [80] with slight modifications (Figure 1). Following reagents were 
used: xylene (Thommen-Furler AG), ethanol (Sigma-Aldrich), cresyl violet (acetate) 
for microscopy Certistain® (Merck), and DEPC treated water (Carl Roth). 
 
 
Figure 1: Cresyl violet staining protocol for FFPE tissue sections. 
5.3 Stroma isolation by LCM 
The stained slides were reviewed by a veterinary pathologist before microdissection 
to identify the stromal areas. Cell types included for isolation were fibroblasts, 
endothelial cells, pericytes, and inflammatory cells. Normal stroma was isolated from 
the same slides as the tumour-associated stroma and at least 2 mm away from the 
tumour cells [81]. Further, the normal stroma had to be located between the normal 
mammary glands and not within the dermis. If the sample did not meet the criteria for 
normal stroma, normal stroma was isolated from another mammary tissue specimen 
of the same dog, extracted and fixed on the same day. Isolation was conducted 
according to manufacturer’s protocol using the ArcturusXT™ Laser Capture 
Microdissection System (Thermo Scientific) and the Arcturus® CapSure® Macro 
LCM Caps (Life Technologies). To validate the proper excision of stromal cells, the 
LCM cap and the region of excision were both checked through microscopy after 
microdissection (Figure 2). The UV-laser or an RNase-away treated scalpel blade 
was used to clean the cap from contaminating epithelial cells in cases where small 
residual amounts of unwanted tissue were co-isolated. The caps containing the 
isolated tissue were placed on 0.5 ml microcentrifuge tubes (Eppendorf® Safe-Lock 
Tubes) and stored at 4°C until microdissection of this sample was concluded, and the 
samples were stored maximum one week at -20°C until mRNA isolation. 
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5.4 Isolation of mRNA 
Extraction of mRNA was performed using the Covaris® truXTRAC FFPE RNA kit 
according to manufacturer’s protocol with small adjustments. To transfer the sample 
into the microTUBE Screw-Cap (Covaris®) a sterile scalpel blade was used to 
remove the membrane from the LCM cap containing the tissue specimen. For 
sonication, the E220 focused ultrasonicator (Covaris®) was used according to 
manufacturer’s protocol. The centrifugation step after crosslink reversal at 80°C was 
skipped (as paraffin had already been removed during staining). In step 13 the RNA 
Elution Buffer was preheated to 70°C to achieve higher mRNA yields. Subsequently, 
mRNA was eluted in two elutions using 30 μl of RNA Elution Buffer in the first round 
and 20 μl in the second round, each of which was collected in a separate tube. After 
finishing mRNA extraction the samples were kept on ice. The mRNA quality and 
mRNA yield was measured according to manufacturer’s protocol using the High 
Sensitivity RNA ScreenTape kit (Agilent Technologies). The eluate was stored at       
-80°C before proceeding further analysis. 
5.5 Next-generation RNA sequencing 
10 ng of RNA from Elution 1 (E1) diluted to a concentration of 0.33 ng/μl in a total 
volume of 30 μl was submitted for next-generation RNA sequencing. The SMARTer 
Stranded Total RNA-seq Kit—Pico Input Mammalian (Clontech/ Takara Bio USA) 
was used according to manufacturer’s protocol for RNA library preparation and 
ribosomal RNA depletion. Single-read sequencing (125bp) was run using the Illumina 
HiSeq 4000 according to standard protocols of the Functional Genomics Centre 
Zurich (FGCZ). Quality control for the resulting NGS reads was performed with 
FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc). Trimmomatic 
[82] (v.0.36, 4 bases hard-trimming from the start, and adapter trimming at the end) 
was used to trim the reads and STAR [83] (version 2.6.0c) was applied to align the 
trimmed reads with the reference genome and transcriptome (FASTA and GTF files, 
respectively, Ensembl, release89, CanFam3.1). Kallisto [84] (version 0.43.1) was 
used for gene expression quantification. For identification of differently expressed 
genes the R/Bioconductor package edgeR [85] (R version: 3.5.0, EdgeR version: 
3.22.1) with the implemented count based negative binominal model was applied 
using the normalisation factor calculated by the trimmed mean of M values (TMM) 
method [86]. 
5.6 Analysis of RNA sequencing data 
Unsupervised hierarchical clustering (p ≤ 0.01, log2 ratio threshold of 0.5) was 
conducted for both, comparison of tumour and normal stroma as well as comparison 
of CAS of metastatic and non-metastatic tumours. 
Gene ontology (GO) enrichment analysis was performed using goseq R Bioconductor 
package [87]. The analysis was run for each cluster as well as for all significantly 
deregulated, up-regulated, and down-regulated genes separately and dividing them 
into the three GO categories termed biological process (BP), molecular function (MF), 
and cellular composition (CC). For the comparison of CAS of metastatic and non-
metastatic tumours no results were displayed for most categories, due to low 
numbers of significantly deregulated genes. Therefore, an additional GO enrichment 
analysis was performed, using the Enrichr software [88, 89]. 
Pathway analysis was performed using the MetaCore™ software (Thomson Reuters) 
analysing the gene set of the 500 most deregulated genes for both comparison 
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conditions mentioned above. As the MetaCore ™ database allows only analysis of 
human, mouse and rat genes, the gene symbol was used for uploading the 
experiment and ‘human’ was selected as the target species. Pathway analysis using 
‘Pathway Maps’ was conducted for the up-regulated, down-regulated, and also for all 
deregulated genes separately (p ≤ 0.03, fold change ≥ 0.5). 
For identification of stromal gene candidates involved in metastasis, all significantly 
deregulated genes of the comparison metastatic versus non-metastatic CAS            
(p ≤ 0.03, fold change ≥ 0.5) were analysed by the Explore DEG app of the FGCZ 
using ‘Feature view’. 
 
5.7 Validation of selected genes by quantitative real-time PCR 
To validate the next-generation RNA sequencing results 16 cases were randomly 
selected (8 metastatic, 8 non-metastatic). The iScript™ cDNA Synthesis Kit (BioRad) 
was used for cDNA preparation according to manufacturer’s protocol. A maximum of 
15 μl of mRNA per reaction were used with a total mRNA input of 15 ng per sample. 
To increase the yield of cDNA for quantitative real-time PCR (RT-qPCR) analysis, the 
TaqMan® PreAmp Master Mix (2x) (Applied Biosystems™) was used to perform 
cDNA preamplification according to manufacturer’s protocol applying 14 PCR cycles. 
After preamplification the samples were diluted by adding 20 μl of nuclease free 
water. To perform RT-qPCR the KAPA PROBE FAST qPCR Kit Master Mix (2X) 
Universal reagents (Kapa Biosystems) was used. The samples were run in duplicates 
on the CFX384 Touch™ Real-Time PCR detection system (BioRad) using 2 μl 
preamlified cDNA per reaction, in a total volume of 10 μl. Relative gene expression 
was quantified as = 2^-(CtTarget-CtHousekeeping), where CtTarget is obtained by 
normalising the resulting CT values against the mean of the three housekeeping 
genes GAPDH, PPIA and B2M. Details regarding primers can be found in (Table 1). 
The TaqMan® primers were obtained from ThermoFisher Scientific and the primers 
for GAPDH from Microsynth (Balgach, Switzerland). All primers were used at final 
concentrations of 900 nM primers and 250 nM probes, except GAPDH used at final 
concentrations of 300 nM primers and 200 nM probe [90]. Validation of the primers 
was either conducted by the manufacturer, or for GAPDH by [90], showing 
approximately 100% amplification efficiency. 
Table 1: List of primers used in this study for RT-qPCR. 
Gene 
target 
Sequence Amplicon 
length (nt) 
Taqman® order 
number or 
Reference 
DIO3 Manufacturer’s proprietary information 96 Cf02688456_g1 
MMP11 Manufacturer’s proprietary information 75 ARFVK2U  
VIT Manufacturer’s proprietary information 68 Cf02657286_m1  
TGFBR3 Manufacturer’s proprietary information 70 Cf02637773_m1 
TGFB2 Manufacturer’s proprietary information 112 Cf02676763_m1 
SFRP1 Manufacturer’s proprietary information 69 Cf02654440_m1 
GAPDH 
Fw: 5’-GCTGCCAAATATGACGACATCA-3’ 
Rev: 5’-GTAGCCCAGGATGCCTTTGAG-3’ 
Probe: 5’-TCCCTCCGATGCCTGCTTCACTACCTT-3’ 
75 [90] 
B2M Manufacturer’s proprietary information 87 Cf02659077_m1 
PPIA Manufacturer’s proprietary information 92 Cf03986523_gH 
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5.8 Graphical representation and statistical analysis of qPCR 
results 
For all statistical analysis and graphical displays of RT-qPCR results, the program 
GraphPad Prism (www.graphpad. com) was used. Relative mRNA levels/expression 
values of the four different sample categories were analysed through 1-way ANOVA 
(p-value with α = 0.05), followed by Bonferroni’s Multiple Comparison Test to assess 
significance between each of the categories. Data is displayed as scatter plots, with 
mean SEM.  
 
5.9 Survival analysis of stromal candidate genes 
To analyse the association of the deregulated genes with survival, the Tumor 
Immune Estimation Resource (TIMER; cistrome.shinyapps.io/timer) web application 
was used [91]. The software checks human data from The Cancer Genome Atlas 
(TCGA). Covariates included in the analysis were age, tumour stage, Breast Invasive 
Carcinoma (BRCA) and its subtype HER-2. For the display of survival differences, a 
Kaplan-Meier Curve was drawn. The parameters were set at 50% for the split 
percentage and 100 months for the survival time. 
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6 Results 
6.1 Paper: “Analysis of Gene Expression Signatures in Cancer-
Associated Stroma from Canine Mammary Tumours Reveals 
Molecular Homology to Human Breast Carcinomas.” 
 
Int. J. Mol. Sci. (2017), 18, 1101; doi:10.3390/ijms18051101 
 
In this first paper, we analysed the expression of nine known human CAS markers by 
RT-qPCR and/or immunohistochemistry in CAS isolated from canine simple 
carcinoma. This was the first report to provide comprehensive expression analysis of 
all these markers in CAS from canine mammary carcinomas. 
My contribution to this paper, of which I am the first author, was to set up the entire 
workflow for LCM of CAS and normal stroma in FFPE tissue samples, and to select 
and analyse the expression of known CAS markers. I also significantly contributed to 
writing of the manuscript. 
  
Results 
 
23 
 
Results 
 
24 
 
Results 
 
25 
 
Results 
 
26 
 
Results 
 
27 
 
Results 
 
28 
 
Results 
 
29 
 
Results 
 
30 
 
Results 
 
31 
 
Results 
 
32 
 
Results 
 
33 
 
Results 
 
34 
 
Results 
 
35 
 
Results 
 
36 
 
Results 
 
37 
 
Results 
 
38 
 
Results 
 
39 
 
Results 
 
40 
 
Results 
 
41 
 
  
Results 
 
42 
6.2 Paper: “An optimised protocol for isolation of RNA from small 
sections of laser-capture microdissected FFPE tissue 
amenable for next-generation sequencing.” 
 
BMC Molecular Biol. (2017) 18:22 doi: 10.1186/s12867-017-0099-7 
 
In this second paper we presented a novel protocol for isolation and analysis of RNA 
from small sections of FFPE tissue that results in much higher RNA yields than the 
conventional extraction protocols and makes it possible to perform next-generation 
RNA sequencing. This was the first report to demonstrate that it is possible to 
perform RNAseq with such small samples isolated from FFPE tissue. 
I contributed to this paper, of which I am shared first author, through teaching of the 
method to the other authors, isolation of several of the cases that were included in 
the study, and by demonstrating that it is feasible to do RNAseq with these samples 
through coordinating a collaboration with the Functional Genomics Center Zurich 
(FGCZ). 
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6.3 Unpublished results: Comparing CAS from metastatic and non-
metastatic canine mammary carcinomas 
The main aim of this third project was to investigate, whether CAS from metastatic 
canine mammary carcinomas differs from that of non-metastatic ones, and if so, 
identify what these differences are. 
6.3.1 Selection of clinical cases and description of tissue sample 
characteristics 
Applying the criteria for case selection described in the Materials and Methods 
chapter, a total of 31 cases could be included in our analysis. 15 dogs (case no. 1-
15) showed metastases in the lymph node at the time of tumour excision, whereas in 
16 dogs (case no. 16-31) no metastases could be found by microscopic examination. 
All 31 samples derived from female dogs, of which 22 were purebreds, 8 were 
crossbreeds and for one dog the breed was not disclosed (Table 2). The age at 
sample collection ranged from 5 to 17 years with a mean age of 11 years. The age of 
tissue blocks included in this study ranged from 7 months to over 120 months, as 
experience in the lab has shown that the age of the block does not significantly 
impair its use for analysis. Cases No. 8, 9, 10, 11, 17, 18, 21, 24, 25 and 27 were 
kindly provided by Prof. R. Klopfleisch (Freie Universität Berlin). For these cases, we 
used the information provided by Prof. Klopfleisch, and no further specification of the 
simple carcinoma subtype was performed. Additionally, no information regarding the 
neutering status or the exact age of samples (at least 120 months) was available for 
these cases. A detailed tabulation of sample characteristics can be found in Table 2 
and further information on the samples from Berlin can be found in [61]. 
6.3.2 mRNA isolation from normal and tumour stroma for next-generation RNA 
sequencing 
To specifically analyse the stromal compartment of canine simple mammary 
carcinomas, LCM was used to specifically isolate CAS and matched normal stroma 
from each case listed in Table 2. The stroma enriched areas were defined by a 
veterinary pathologist before starting LCM to ensure the correct isolation of stromal 
cells. Further, validation was conducted by taking pictures of the area of interest 
before and after microdissection, which included the inspection of the excised tissue 
on the cap (for examples, see Figure 2). 
To analyse the extracted tissue by next-generation RNA sequencing, mRNA was 
isolated according to our previously published protocol [77]. The total mRNA yield of 
the first elution (E1) ranged from 23.7 ng to 654 ng and the mRNA quality of E1, 
determined by the RNA integrity number (RIN), varied between 1 and 4 with a mean 
value of 2 (Table 3), as expected [77]. As these values were well within the range 
amenable to RNAseq [77], CAS and normal stroma from all 31 cases were submitted 
for RNAseq analysis. 
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Table 2: Overview of cases included in this study. Clinical data from dogs with simple mammary 
carcinoma; Case # = case number as referred to within this study; Case-ID = case identification 
number; f/n = female, neutered; n.d. = not disclosed; age = age at excision of tumour; age of sample = 
time between initial tumour excision and sampling of stroma/RNA extraction. > 120 denotes samples 
from Berlin which are at least 120 months old, but for which no exact age could be defined. 
Case # Case-ID Gender Breed Age 
(years) 
Subtype of 
simple carcinoma    
*not specified for 
samples from 
Berlin 
Metastases 
in lymph 
node 
Histologic 
Grade 
Age of 
sample 
(months) 
1 H11-0640-3 
(M2) 
f Volpino Italiano 11 solid + Grade III 85 
2 H12-0226-3/4 
(M3) 
f Labrador Retriever 13 comedocarcinoma + Grade III 75 
3 H12-2699-4 
(M4) 
f Cocker Spaniel 11 solid + Grade III 67 
4 H13-1198-1/3 
(M5) 
f n.d. 11 solid + Grade III 60 
5 H10-0986-2 
(M6) 
f Irish Setter 10 tubulopapillary + Grade II 97 
6 H16-0106-1/2 
(M7) 
f/n Crossbreed 14 solid + Grade III 28 
7 H14-1216-1/4 
(M8) 
f Papillon 17 solid + Grade III 48 
8 V822/07AF 
(M10) 
f/n.d. American Pitbull 9 *simple carcinoma + Grade III > 120 
9 V833/07BRK 
(M11) 
f/n.d. Rottweiler 10 *simple carcinoma + Grade III > 120 
10 2243/07CRK 
(M12) 
f/n.d. Bavarian Mountain Hound 13 *simple carcinoma + Grade III > 120 
11 1232/08RKC 
(M13) 
f/n.d. West Highland White 
Terrier 
16 *simple carcinoma + Grade II > 120 
12 H13-1669-2 
(M14) 
f American Staffordshire 
Terrier 
12 tubular + Grade II 59 
13 H11-2840-1 
(M15) 
f Border Collie-Mix 14 tubulopapillary + Grade II 80 
14 H16-1705-2/4 
(M31) 
f Vizsla 11 micropapillary + Grade II 25 
15 H15-0838-1 
(M32) 
f Poodle-Mix 14 comedocarcinoma + Grade II 40 
16 H17-0434-1 
(M9) 
f Golden Retriever 9 tubular-solid - Grade I 15 
17 V830/07BRK 
(M16) 
f/n.d. Cocker Spaniel-Mix 12 *simple carcinoma - Grade III > 120 
18 2047/07ARK 
(M17) 
f/n.d. Labrador Retriever 11 *simple carcinoma - Grade III > 120 
19 H11-0316-4 
(M18) 
f Old English Sheepdog 11 tubular - Grade I 88 
20 H17-1914-2 
(M19) 
f Miniature Pinscher 13 tubular - Grade I 9 
21 1937/07ARK 
(M20) 
f/n.d. Dalmatian 10 *simple carcinoma - Grade II > 120 
22 H17-2696-1 
(M21) 
f/n Brittany 9 solid - Grade II 7 
23 H17-2039-1 
(M22) 
f/n Border Collie-Mix 10 tubular - Grade II 9 
24 279/08RKA 
(M23) 
f/n.d. German Shepherd-Mix 13 *simple carcinoma - Grade III > 120 
25 264/08RKA 
(M24) 
f/n.d. German Shepherd-Mix 9 *simple carcinoma - Grade III > 120 
26 H11-0455-1 
(M25) 
f Havanese 9 solid - Grade II 89 
27 2194/07CRK 
(M26) 
f/n.d. Crossbreed 11 *simple carcinoma - Grade III > 120 
28 H16-2622-3 
(M27) 
f French Bulldog 5 tubular - Grade I 21 
29 H14-2512-2 
(M28) 
f Staffordshire Bull Terrier n.d tubular - Grade I 45 
30 H14-2537-1/2 
(M29) 
f Jack Russell Terrier 9 cystic-papillary - Grade I 45 
31 H16-2188-2 
(M30) 
f Podenco 9 comedocarcinoma - Grade I 23 
 
Results 
 
56 
 
Figure 2: Excision of CAS and normal stroma by LCM. To validate proper isolation of stromal cells, 
pictures of the specimen were taken at x10 magnification a) before dissection, b) after dissection, and 
c) of the cap. Case-IDs: A: H11-2840-1 (Case 13), metastatic; B: H11-0316-4 (Case 19), non-
metastatic. 
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Table 3: Overview of RNA yields and RIN values of samples included in this study. RIN values and 
total yield of RNA in elution 1 (E1) are tabulated according to case# and type of tissue (normal stroma 
vs. CAS) in metastatic (left) versus non-metastatic (right) cases. 
metastatic cases non-metastatic cases 
Case # RIN of E1 
 
Total mRNA 
yield of E1 
(ng) 
Case # RIN of E1 
 
Total mRNA 
yield of E1 
(ng) 
1 Normal stroma 
CAS 
3.3 
3.0 
103.5 
188.7 
16 Normal stroma 
CAS 
2.4 
3.4 
198.9 
60.3 
2 Normal stroma 
CAS 
3.3 
3.1 
654 
126.3 
17 Normal stroma 
CAS 
2.8 
1.1 
147.3 
244.8 
3 Normal stroma 
CAS 
2.4 
2.7 
30.6 
49.2 
18 Normal stroma 
CAS 
2.8 
3.0 
52.5 
109.8 
4 Normal stroma 
CAS 
1.0 
3.0 
74.1 
82.8 
19 Normal stroma 
CAS 
3.0 
3.8 
56.4 
103.5 
5 Normal stroma 
CAS 
3.2 
3.6 
48.6 
61.5 
20 Normal stroma 
CAS 
3.3 
3.5 
43.5 
63.9 
6 Normal stroma 
CAS 
2.9 
2.8 
183.3 
141.6 
21 Normal stroma 
CAS 
2.8 
3.1 
110.1 
111.9 
7 Normal stroma 
CAS 
2.8 
1.0 
177 
124.5 
22 Normal stroma 
CAS 
3.3 
3.7 
35.4 
39.3 
8 Normal stroma 
CAS 
1.1 
2.5 
120 
118.2 
23 Normal stroma 
CAS 
2.6 
3.1 
83.7 
62.4 
9 Normal stroma 
CAS 
1.6 
1.0 
351 
220.8 
24 Normal stroma 
CAS 
2.4 
2.9 
135.9 
81.3 
10 Normal stroma 
CAS 
2.3 
3.9 
128.7 
67.8 
25 Normal stroma 
CAS 
2.9 
3.8 
62.1 
48 
11 Normal stroma 
CAS 
3.4 
2.8 
165 
81.3 
26 Normal stroma 
CAS 
3.4 
2.4 
51.6 
202.5 
12 Normal stroma 
CAS 
3.5 
1.0 
71.1 
114 
27 Normal stroma 
CAS 
3.1 
2.8 
51.6 
59.1 
13 Normal stroma 
CAS 
3.1 
1.0 
101.7 
84.9 
28 Normal stroma 
CAS 
3.3 
3.3 
31.5 
37.2 
14 Normal stroma 
CAS 
3.5 
2.9 
23.7 
35.7 
29 Normal stroma 
CAS 
3.3 
3.7 
49.2 
30.6 
15 Normal stroma 
CAS 
1.5 
1.5 
63 
32.4 
30 Normal stroma 
CAS 
4.0 
3.5 
33.3 
26.9 
    31 Normal stroma 
CAS 
3.4 
2.8 
43.2 
47.4 
 
6.3.3 Gene expression analysis of normal and tumour stroma from simple 
canine mammary tumours using RNAseq 
To characterise differences of stromal gene expression in the different compartments 
of canine mammary tumour samples, an unsupervised hierarchical clustering of all 
samples was performed. As expected, the gene expression pattern clearly separated 
the normal stroma and CAS into two groups, demonstrating that CAS clearly differs 
from normal stroma in these canine samples and validating our isolation approach 
(Figure 3). Using a significance threshold of p ≤ 0.01 and a log2 ratio threshold of 0.5 
to compare CAS and normal stroma, a total of 1999 genes were identified as 
significantly differentially expressed. 780 genes were up-regulated in CAS compared 
to normal stroma, whereas 1219 genes were down-regulated. Gene ontology 
analysis of the deregulated genes identified six clusters (indicated by coloured blocks 
on the Y axis in Figure 3). To understand the biological role of genes involved in each 
of these clusters, gene set enrichment analysis was conducted. Analysis of biological 
processes in these clusters identified the following main categories: cluster 1 (blue, 
559 genes) contained genes involved in cell adhesion and migration, cluster 2 
(green, 174 genes) and 5 (red, 172 genes) showed genes involved in immune 
Results 
 
58 
response, cluster 3 (cyan, 46 genes) exhibited genes important for endodermal cell 
differentiation and collagen fibril organisation, cluster 4 (orange, 851 genes) showed 
genes related to signal transduction and angiogenesis, and cluster 6 (yellow, 197 
genes) contained genes related to blood and lymph vessel development (Figure 4). 
Importantly, all of these categories are consistent with changes in stromal biology, 
thus further validating the isolation of CAS and normal stroma. To investigate 
whether the different histological tumour grades clustered according to gene 
expression, the grade of each sample was marked with a colour. However, no clear 
clustering of the different tumour grades could be detected (Figure 3). To get further 
insight into the most deregulated pathways between CAS and normal stroma, the 
MetaCore™ program was used. The 500 most deregulated genes were analysed 
with pathway maps setting a threshold of 0.5 and p-value of 0.05. For the up-
regulated genes TGFβ signalling, ECM remodelling, cell adhesion and EMT were 
among the top 10 pathways, whereas immune response and angiogenesis were 
present in the top 10 pathways of the down-regulated genes (Figure 5). Taken 
together, these results demonstrated the validity of our approach to isolate and 
analyse CAS and normal stroma from FFPE subsections by RNAseq, and revealed 
several interesting changes between normal and tumour stroma in canine mammary 
carcinomas. 
 
 
Figure 3: Hierarchical clustering and heatmap of 31 canine mammary tumour samples analysed by 
RNA sequencing (p ≤ 0.01, log2 ratio threshold of 0.5). Normal stroma (left) and CAS (right) were 
clustered separately. Each row features one gene, and each column represents one sample. The red 
and blue colours represent the relative gene expression level of each gene for each sample in relation 
to all the other samples. Red indicates a relative up-regulation and blue indicates a relative down-
regulation of the gene. The genes were clustered into six groups according to their expression pattern 
and marked with different colours on the Y-axis (see legend on the right). The histological tumour 
grade (grade I-III) is indicated for each gene on the upper X-axis (see legend on the right). 
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Figure 4: Gene ontology enrichment analysis for each cluster of deregulated stromal genes. Term = 
affected biological process, ID = Gene ontology accession number, p = p-value indicating the 
significance of overlap between biological process and the canine gene dataset. 
 
 
Figure 5: Pathway analysis of up-regulated and down-regulated genes of CAS. The X-axis shows the 
-log(pValue) describing the extent of the intersection between the stromal genes and all the genes 
involved in each pathway. The 10 most significant pathways are displayed. 
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6.3.3.1 Stromal gene expression of selected CAS markers in canine mammary 
tumours 
We have previously analysed the expression of 9 known human CAS markers in 
stromal samples from canine simple mammary carcinomas using RT-qPCR and/or 
IHC [75, 76]. To see if the results from this study were comparable with the new 
results obtained by RNAseq with a different patient cohort, we analysed the 
expression patterns of the same genes in our new dataset. ACTA2 (the gene 
encoding αSMA), COL1A1, CXCL12, FAP, CAV1, IL6, MMP2, and PDGFRB could 
be identified among the significantly deregulated genes, while FGF2 was not 
detected in the new dataset. Similarly to our previous study, ACTA2, COL1A1 and 
FAP were significantly up-regulated in CAS compared to normal stroma, and 
CXCL12 was significantly down-regulated, thus confirming our previous results 
(Figure 6A, B, C and E). While our previous study did not detect significant changes 
in MMP2, PDGFRB and IL6 expression, mostly due to sample and analysis 
limitations, we now found MMP2 to be significantly up-regulated in CAS compared to 
normal stroma, whereas PDGFRB and IL6 were significantly down-regulated (Figure 
6D, G and H). . Additionally, CAV1, expression of which had only been analysed by 
IHC in our previous study, showed a significant reduction in CAS compared to normal 
stroma in the new dataset (Figure 6F). In summary, these results validated the 
deregulation for ACTA2, COL1A1, FAP and CXCL12 observed in our previous study, 
and further underline the validity of our analytic approach. Additionally, the new 
dataset also revealed CAV1, MMP2, IL6 and PDGFRB to be significantly deregulated 
in the stroma of canine mammary tumours. 
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Figure 6: Expression analysis of selected human CAS markers, in CAS from canine mammary 
tumours. A: ACTA2, B: COL1A1, C: FAP, D: MMP2, E: CXCL12, F: CAV1, G: PDGFRB, and H: IL6. 
Boxplots display the expression levels detected by RNAseq for the selected genes in normal stroma 
and CAS, respectively. The centre of the box indicates the median, while the top and bottom mark the 
75th and 25th percentile, respectively. The whiskers indicate the 25th and 75th percentile +/- 1.5 x 
interquartile range. Expression levels detected in normal stroma are marked in orange, and expression 
levels in CAS are marked in blue. Gene expression levels (signal) indicating the amount of transcripts 
detected in each sample, are displayed on the Y-axis. The name of the gene and the ENSEMBL 
identification number are displayed in the grey box on top of each boxplot. P = p-value, fold change = 
the difference of the mRNA levels in CAS over to normal stroma. 
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6.3.4 Identification of differentially expressed stromal genes comparing 
metastatic and non-metastatic canine mammary tumours 
To identify changes potentially associated with tumour progression, we compared 
stromal gene expression of metastatic vs. non-metastatic simple canine mammary 
carcinomas. While the heatmap showed a similar gene expression pattern for normal 
stroma from the metastatic and non-metastatic samples, clear differences could be 
found in the CAS of metastatic versus non-metastatic cases (Figure 7). Using a 
significance threshold of 0.01 and log2 ratio threshold of 0.5, we identified 134 
differentially expressed genes between CAS from metastatic vs. non-metastatic 
samples, including 68 up-regulated genes and 66 down-regulated genes in the 
metastatic group compared to the non-metastatic group. Six clusters were identified 
by gene ontology analysis and include following biological processes: cluster 1 (blue, 
12 genes) showed genes involved in actin filament crosslinking, migration, cell 
adhesion and epithelial structure maintenance, cluster 2 (red, 23 genes) contained 
genes involved in ion homeostasis, regulation of cell cycle and metabolism, cluster 3 
(orange, 27 genes) included genes involved in cell differentiation, osteoblast 
proliferation, immune response and inflammation cluster 4 (cyan, 7 genes) exhibits 
genes important for apoptosis, regulation of nuclear division, cell adhesion, 
embryonic development, and angiogenesis, cluster 5 (yellow, 51 genes) showed 
genes involved in hormone biosynthesis, coagulation and bone remodelling, cluster 6 
(green, 14 genes) contained genes related to immune response and inflammation 
(Figure 8). Again, there was no clear clustering of different grades according to gene 
expression (Figure 7). The 500 most deregulated genes were analysed using 
MetaCore™ with a threshold set at 0.5 and p-value of 0.03. Pathway analysis of the 
up-regulated genes in the CAS of metastatic tumours showed involvement in 
chemotaxis, regulation of apoptosis and immune response. The down-regulated 
genes in the metastatic samples revealed TGFβ signalling, gonadotropin-releasing 
hormone (GnRH) signalling, tissue factor signalling, and genes involved in immune 
response and lipid metabolism among the top 10 deregulated pathways (Figure 9). 
Taken together, these results identify clear differences in CAS between metastatic 
and non-metastatic canine mammary carcinomas, suggesting that stromal changes 
can potentially be used as markers for tumour progression, and that some of the 
observed changes might present therapeutic targets to inhibit tumour metastasis. 
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Figure 7: Hierarchical clustering and heatmap of 31 canine mammary tumour samples analysed by 
RNA sequencing (p ≤ 0.01, log2 ratio threshold of 0.5). Normal stroma of non-metastatic and 
metastatic samples (left) and CAS of non-metastatic and metastatic samples (right) were clustered 
separately. Each row features one gene, and each column represents one sample. The red and blue 
colours represent the relative gene expression level of each gene for each sample in relation to all the 
other samples. Red indicates a relative up-regulation and blue indicates a relative down-regulation of 
the gene. The genes were clustered into six groups according to their expression pattern and marked 
with different colours on the Y-axis (see legend on the right). The histological tumour grade (grade I-III) 
is indicated for each gene on the upper X-axis (see legend on the right). 
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Figure 8: Gene ontology enrichment analysis for each cluster of deregulated stromal genes 
comparing metastatic vs. non-metastatic samples. Term = affected biological process, ID = Gene 
ontology accession number, p = p-value indicating the significance of overlap between biological 
process and the dataset. 
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Figure 9: Pathway analysis of genes up-regulated (left) and down-regulated (right) in CAS from 
metastatic compared to non-metastatic samples. The X-axis shows the -log(pValue) describing the 
extent of the intersection between the stromal genes from metastatic tumours and all the genes 
involved in each pathway. The Y-axis displays the 10 most significant pathways. 
 
6.3.4.1 Identification of stromal gene candidates involved in metastasis of 
canine mammary carcinomas 
To identify genes which could potentially play an important role during tumour 
progression, the list with deregulated genes between non-metastatic and metastatic 
CAS was further analysed manually. All genes with a fold change ≥ 0.5 and p-value ≤ 
0.03 were included in the analysis. First, the median level of gene expression for 
each gene in each condition (CAS and normal stroma from metastatic and non-
metastatic samples) was analysed using “Feature view”. Interesting patterns that 
were identified included unchanged expression in normal and non-metastatic 
tumours, with a strong increase or decrease in the metastatic tumours (e.g. Figure 
10A), or significant differences between non-metastatic and metastatic CAS (e.g. 
Figure 10B). 76 genes displayed an interesting pattern, and available literature was 
checked for a known involvement in cancer formation. 33 of the deregulated genes 
showed a known interesting association with processes involved in tumorigenesis, 
and could be divided into the main categories metabolism, angiogenesis and 
coagulation, tumour progression as well as hypoxia-inducible factor 1 (HIF-1) 
signalling, TGFβ signalling, immune response, and ECM remodelling (Table 4). Due 
to their established involvement in CAS biology in human breast cancer, several 
genes pertaining to the last four groups (HIF-1 signalling, TGFβ signalling, immune 
response, and ECM remodelling) were selected for closer analysis and validation. 
The deregulated genes included in these four groups can be found in Table 4. 
 
Results 
 
66 
 
Figure 10: Boxplots of two genes A: DIO3 and B: COL14A1 representative for genes showing an 
interesting pattern of median gene expression level changes. Expression levels are displayed for 
normal stroma of metastatic tumours (orange), CAS of metastatic tumours (blue), normal stroma of 
non-metastatic tumours (green), CAS of non-metastatic tumours (yellow). P = p-value, fold change = 
the difference of the mRNA levels in CAS of metastatic tumours over CAS of non-metastatic tumours 
in relation to the respective normal stroma. 
 
Table 4: Overview of the 33 interesting significantly deregulated genes included in the seven groups 
TGFβ signalling, HIF-1 signalling, immune response, and ECM remodelling, tumour progression, 
angiogenesis and coagulation, and metabolism 
Up-regulated genes Down-regulated genes 
TGFβ signalling 
DIO3 TGFB2, TGFBR3, LTBP4 
HIF-1 signalling 
DIO3, WT1 TGFB2, STC2, RHOBTB3 
Immune response 
GIMAP8, BIN2, HLA-DRB1, FASLG  
ECM remodelling 
MMP11, OLFML2B FN1, VIT, COL14A1 
Tumour progression 
CTHRC1, MKI67, immunity-related GTPase 
family M protein 1 (ENSCAFG00000000497) 
AKAP12, SLIT2, ABLIM1, SEMA3G, LIMCH1, 
SFRP1, IGFBP5 
Angiogenesis and coagulation 
HHIPL1, F5 F13A1, CD36, GAS6, FBLN7 
Metabolism 
 CD36, APOE 
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6.3.5 Validation of next-generation RNA sequencing by RT-qPCR 
To validate the gene expression changes between CAS of the metastatic over non-
metastatic dataset, quantitative real-time PCR (RT-qPCR) was run with 16 samples 
checking the expression of 7 selected genes including matrix metalloproteinase 11 
(MMP11), vitrin (VIT), transforming growth factor beta 2 (TGFB2), transforming 
growth factor receptor 3 (TGFBR3), deiodinase 3 (DIO3), procollagen C-
endopeptidase enhancer 2 (PCOLCE2), and secreted frizzled related protein 1 
(SFRP1) (Figure 11 and Table 4). PCOLCE2 and SFRP1 are two interesting genes 
that were previously identified in CAS of canine mammary tumours in the context of a 
different project in our group and thus also included in the analysis. 1-way ANOVA 
analysis of gene expression levels in all four conditions detected significant 
differences for MMP11, VIT, TGFB2, TGFBR3 and PCOLCE2 (Figure 11). While the 
expression trends closely matched the sequencing results, the difference between 
CAS of the metastatic and non-metastatic samples only reached significance for 
MMP11 when using Bonferroni’s Multiple Comparison Test to compare all conditions 
with each other (Figure 11A). MMP11 showed a significant up-regulation in CAS of 
metastatic tumours compared to all other conditions. TGFB2 displayed a significant 
up-regulation when comparing the normal stroma of metastatic tumours with CAS of 
non-metastatic tumours (Figure 11B). The trend of lower TGFB2 expression in CAS 
from metastatic compared to non-metastatic samples is clearly visible. VIT 
demonstrated a significant down-regulation between the comparison of normal 
stroma from non-metastatic tumours and CAS of metastatic tumours (Figure 11C). 
Again, the trend of lower VIT expression in CAS from metastatic compared to non-
metastatic samples can be seen. TGFBR3 expression was significantly down-
regulated between normal stroma and CAS (Figure 11D). Also for TGFB3, the trend 
of lower expression in CAS from metastatic compared to non-metastatic samples is 
obvious. A similar result was obtained for PCOLCE2, revealing a significant down-
regulation in CAS compared to the normal stroma of non-metastatic tumours (Figure 
11E). Finally, also for PCOLCE2 expression in CAS from metastatic samples is 
clearly lower than in non-metastatic samples. No significant deregulation between all 
four conditions could be found for SFRP1 (Figure 11F) and DIO3 (Figure 11G), even 
though the tendency of gene expression change between metastatic and non-
metastatic CAS for both genes is similar to the results from RNAseq. Taken together, 
these results further support the findings from the sequencing analyses and identify 
several interesting deregulated targets in CAS between metastatic and non-
metastatic canine mammary tumours. 
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Figure 11: Relative mRNA levels of stromal genes in CAS of metastatic tumours, CAS of non-
metastatic tumours and respective normal stroma, measured by RT-qPCR. Scatter plots for               
A: MMP11, B: TGFB2, C: VIT, D: TGFBR3, E: PCOLCE2, F: SFRP1, G: DIO3. The value of each 
sample is displayed for each condition with a mean value ±SEM. Significance between the different 
conditions was calculated using ANOVA, and is indicated with (* = p < 0.05), (** = p < 0.01) and        
(*** = p < 0.005), respectively. 
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6.3.6 Association of canine stromal markers of metastatic canine mammary 
carcinomas with survival of human breast cancer patients 
Finally, we were interested to see whether some of the identified deregulated genes 
of the metastatic canine mammary carcinomas were associated with prognosis in 
human breast cancer. To assess this, we performed survival analysis of the selected 
33 genes (Table 4) using the TIMER software, which allows the assessment of gene 
expression levels in whole tumours in correlation to survival from TCGA data. The 
datasets of human breast cancer patients with invasive carcinomas were checked 
setting a follow-up time of 100 months. A significant association with worse survival 
was found for down-regulation of TGFB2, VIT, collagen type XIV alpha 1 chain 
(COL14A1), slit guidance ligand 2 (SLIT2), and semaphorin 3G (SEMA3G) (Figure 
12). Of note, TGFB2 was significantly associated with survival only when analysing 
data of the HER-2 subtype. These results further suggest the presence of strong 
similarities in expression changes in CAS between canine and human breast cancer 
specimen. Moreover, they identify a number of dysregulated genes that are related to 
tumour malignancy and survival in both species. 
In conclusion, our study provides evidence that CAS in canine mammary tumours 
undergoes strong reprogramming mechanisms, and that a number of genes is 
significantly differentially expressed between CAS from metastatic and non-
metastatic tumours. Finally, we demonstrate the deregulation of some of these genes 
in metastatic canine mammary tumours is predictive of a worse prognosis also in 
human breast cancers. These data support the usefulness of comparatively 
analysing CAS between canine mammary tumours and human breast cancer to 
identify potential markers of disease progression as well as novel therapeutic targets 
to inhibit tumour metastasis. 
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Figure 12: Kaplan-Meier Survival Curves displaying significant association of TGFB2, VIT, COL14A1, 
SLIT2, SEMA3G and prognosis in human breast cancer patients. The X-axis shows the follow-up time 
of human patients and the Y-axis lists the percentage of patients still alive. The name of the tested 
gene is marked in the upper grey box, the type of human breast cancer is presented in the grey box 
on the right. BRCA = Breast Invasive Carcinoma, BRCA-HER2 = HER-2 subtype of Breast Invasive 
Carcinoma. The red line indicates patient samples with an up-regulation of the gene and blue 
indicates patients samples showing down-regulation of the gene with a split percentage set at 50%. 
Log-rank P = p-value indicating the significance of the selected gene related with survival in human 
breast cancer patients. 
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7 Discussion 
Breast cancer is the most frequent cancer both in women and female dogs. Several 
lines of evidence suggest spontaneously occurring mammary tumours in the dog as 
an interesting candidate for comparative oncology to better understand the biology of 
cancer and uncover novel prognostic biomarkers as well as therapeutic targets [2, 
35, 48, 92]. To date, in a significant number of both humans and dogs, the clinical 
and histopathologic indicators that are used are not able to predict the clinical 
outcome. Therefore, new indicators are needed to more accurately diagnose and 
treat patients [48]. Especially with regards to metastasis, major efforts are being 
made to identify potential biomarkers and therapeutics to diagnose and treat cancer 
early, and to enhance survival of cancer patients, as metastases are the main factor 
of cancer-related deaths both in humans and dogs [1, 38, 66]. 
CAS is emerging as a central player in cancer biology, and it has been shown to 
support cancer initiation, growth, metastasis and resistance of tumour cells to cancer 
therapy [7, 9, 11, 12, 14]. Thus, the identification of predictive biomarkers in CAS as 
well as targeting of CAS components for therapeutic purposes are considered highly 
interesting options to advance cancer patient care [7, 8, 12, 14]. While mechanisms 
in CAS in human breast cancer are slowly being unveiled, CAS in canine mammary 
tumours remains largely uncharacterized. So far, just very few studies have 
investigated the involvement of stromal genes in canine mammary tumours, all of 
which were limited to very few markers that were analysed mostly by 
immunohistochemistry. To better understand the mechanisms involved in CAS 
formation of canine mammary tumours and be able to identify commonalities and 
differences between canine and human CAS, we set out to analyse the gene 
expression of CAS from canine simple mammary carcinomas. Specifically, the aims 
of my thesis were the following: 
1) Establish an approach to analyse the expression of selected CAS markers for 
human breast cancer in CAS from canine mammary carcinomas. 
2) Develop a protocol to analyse CAS and normal stroma from FFPE tissues by 
next-generation sequencing. 
3) Analyse CAS and normal stroma from non-metastatic versus metastatic 
canine mammary carcinomas to investigate the changes in canine CAS and 
identify differentially regulated genes that could potentially be used as 
prognostic or therapeutic targets. 
 
7.1 First aim: Analysis of selected CAS markers for human breast 
cancer in CAS from canine mammary carcinomas 
In order to investigate if CAS in canine mammary carcinomas is comparable to 
human breast cancer, we analysed the expression of selected CAS markers for 
human breast cancer in canine tumour samples using laser-capture microdissection 
[93]. Our results suggested similarities in CAS biology between canine and human 
breast cancer, but also revealed some differences between the two species [75, 76]. 
This publication was the first report to provide an expression analysis of several of 
the most important human CAS markers in canine mammary carcinomas. 
While yielding important results, this study was however limited, as analysis by RT-
qPCR only yields results on the genes that have been chosen a priori. Thus, this kind 
of analysis is entirely relying on defined candidate genes, which precludes an 
unbiased view. RNAseq would allow much broader and less biased analysis of the 
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samples. However, as FFPE fixation is known to heavily impact on the quantity and 
the quality of RNA, the use of extremely small amounts of RNA recovered from laser-
capture microdissected FFPE tissue was considered as incompatible with RNAseq. 
Nevertheless, we decided to try and improve the available RNA extraction protocols 
for FFPE tissue with the aim to perform RNAseq. 
 
7.2 Second aim: Development of an optimised RNA extraction 
protocol from laser-capture microdissected FFPE samples 
amenable for RNAseq 
FFPE tissues are a large and very valuable resource of patient-derived tissue 
samples. However, isolation and analysis of RNA from FFPE tissues has proven 
challenging due to chemical alteration of nucleic acids caused by formalin fixation 
[94-97]. In this second part of my thesis, the aim was to improve our RNA isolation 
technique from laser-capture microdissected samples in a manner that would allow 
next-generation RNA sequencing. Through optimisation of a protocol based on 
focused ultrasonication, we were able to develop an approach to increase the yields 
of RNA from laser-capture microdissected FFPE tissue samples and make them 
amenable to RNAseq analysis [77]. This was the first report to show that small 
amounts of RNA isolated from FFPE tissues can be analysed through RNAseq. 
One potential limitation of the approach is the low RNA quality that can be isolated 
from FFPE tissue [94-97]. This is the main reason that most LCM-based studies to 
date have been using fresh-frozen tissue rather than FFPE sections even for RT-
qPCR analyses [94]. RNA degradation and crosslinking through FFPE occurs mainly 
at the fixation stage, and cannot be strongly influenced afterwards. Therefore, to 
avoid the introduction of artificial biases due to sample quality differences, it is very 
important for the analysis of FFPE tissues by next-generation RNAseq that RNA of 
similar quality is compared. Whenever possible, in our approach we strived to isolate 
the different areas from the same tissue section to ascertain that both samples have 
undergone the same treatment. If not possible, different samples from the same 
patient taken on the same day and fixed in the same manner were used. While these 
precautions certainly limit the introduction of large biases, they cannot completely be 
avoided. Thus, validation of results through RT-qPCR and/or immunohistochemistry 
should always be performed before finalising any claims. Another important aspect is 
that the low amount of RNA that is submitted for sequencing makes detection of very 
low expressed genes difficult. Therefore, results are biased towards more highly 
expressed genes, because these can be reliably detected and quantified. 
Nevertheless, as the analysis setup always compares normal stroma with CAS from 
the same patient, observed changes are likely to be true. A possible approach to 
further validate our novel protocol would be to analyse in parallel CAS and normal 
stroma isolated from both FFPE tissue and fresh frozen tissue from the same 
sample. While this would have exceeded the scope of our study, it can be considered 
for future projects. Concluding, this novel approach to analyse FFPE tissue 
subsections has the potential to become a very valuable tool for biomedical research. 
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7.3 Third aim: Analysis of CAS and normal stroma from non-
metastatic versus metastatic canine mammary carcinomas 
My third aim was to investigate the changes in CAS between metastatic and non-
metastatic canine mammary carcinomas, and identify differentially regulated genes 
that could potentially be used as prognostic or therapeutic targets. For this, our 
recently developed RNAseq protocol was used to analyse CAS and matched normal 
stroma isolated from FFPE samples by LCM. 
7.3.1 Characteristics of cases and tissue samples included in the study 
31 clinical cases of canine simple mammary carcinomas were selected, including 15 
metastatic and 16 non-metastatic cases (Tables 2 and 3). Among the 31 cases, no 
dog breed was overrepresented. The mean age of dogs included in this study was 11 
years, which is in accordance with values from literature [36, 38]. Information 
regarding neutering was available for 21 dogs. Only 3 dogs were neutered, matching 
literature which shows elevated risks of mammary carcinoma development in intact 
bitches. Unfortunately, no information regarding the age at time of neutering was 
available for the 3 neutered dogs which developed mammary carcinomas. The age of 
FFPE tissue blocks included varied between 7 months and over 120 months. We did 
however not observe sample-age dependent differences in mRNA quality and 
quantity (Table 3), emphasising the value and usability of these patient materials for 
research purposes. 
Among the metastatic cases the solid histological subtype was overrepresented, 
whereas the tubular subtype was diagnosed more frequently in the non-metastatic 
cases. A difference was also seen in the distribution of histological tumour grades 
with grade I tumours only diagnosed in non-metastatic cases. Most tubular 
carcinomas were classified as grade I. These results are in line with other studies 
that found association of histological subtypes and tumour grades in canine 
mammary tumours as well as association of these histological criteria with metastasis 
[48, 51, 52, 54]. However, a general correlation between histological criteria and 
prognosis was not obvious, as solid and comedocarcinomas, both of which are 
usually associated with worse prognosis, as well as tumours classified as grade II or 
grade III were also found among the non-metastatic cases (Table 2). Furthermore, 
several tubular and tubulopapillary carcinomas, generally associated with better 
prognosis, were among metastatic cases. A widely known and important point of 
criticism is the improper application and interpretation of histological criteria or use of 
different grading systems by different pathologists, leading to various diagnostic 
results [32, 51]. Taken together, new indicators to diagnose canine mammary 
carcinomas and to allow more accurate forecasting are required [48]. 
 
7.3.2 Differences in gene expression between normal stroma and CAS in 
canine mammary tumours 
Unsupervised hierarchical clustering of samples clearly revealed significant changes 
in gene expression in CAS compared to matched normal stroma (Figure 3). This 
validated our approach to selectively isolate these tissues by laser-capture 
microdissection, and also demonstrated that CAS in canine mammary carcinomas 
undergoes strong reprogramming. A comparison of gene expression patterns 
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revealed no clear association with histological grades (Figure 3), matching the 
conclusions drawn in the previous chapter. 
Gene ontology analysis of the most significantly deregulated genes revealed that 
genes mostly up-regulated in CAS are involved in cell-adhesion, cell migration, 
collagen fibril organisation, endodermal cell differentiation and immune response 
(Figure 4). All of these processes are consistent with changes in stromal biology. 
Collagen fibril organisation is often altered in tumour tissues leading to 
disorganisation of the ECM, thus possibly supporting the invasion of cancer cells [2, 
7, 8, 11, 14]. Moreover, enhanced cell motility and migration of cancer cells is 
achieved through down-regulation of cell-adhesion molecules (E-cadherin) and the 
acquisition of a mesenchymal phenotype (EMT) induced by soluble factors like 
MMPs or TGFβ secreted by stromal cells [8, 9, 11, 15]. EMT and TGFβ signalling are 
also known to be involved in endodermal differentiation providing a possible 
explanation for the identification of this process [98, 99]. Altered immune response is 
another main category supporting tumour growth and progression [8, 9, 21]. Among 
the top 5 biological processes positive regulation of T-helper type 1 cells could be 
found suggesting a proinflammatory microenvironment, which is associated with 
better prognosis in cancer patients [100]. However, variable effects on patient 
outcome are described, due to variable effects of cytokines in the tumour 
microenvironment [101].  
Genes mostly down-regulated in CAS were involved in signal transduction, 
angiogenesis and immune response (Figure 4). These processes are known to be 
altered in tumours and to support tumour progression [8, 9, 11]. Angiogenesis is 
important for the survival of tumour cells, as blood vessels provide oxygen and 
energy-rich metabolites [8, 11]. In our dataset genes involved in the establishment of 
endothelial barrier are down-regulated, which can facilitate intravasation of cancer 
cells, resulting in distant metastasis. Moreover, down-regulation of immune response, 
especially CD8+ T cells, in tumour tissue is shown to be associated with worse 
prognosis in cancer patients [9, 11, 14]. 
Detailed analysis of the pathways of the up- and down-regulated genes revealed 
similar categories as for the biological processes by gene ontology. For the up-
regulated genes pathways involved in TGFβ signalling, ECM remodelling, EMT, cell 
adhesion and migration were overrepresented, and pathways involved in 
angiogenesis and immune response were also present (Figure 5). The main 
pathways affected regarding the immune system were associated with complement 
activation. The function of complement is still not fully understood, as a dual role has 
been described, where the complement either destroys cancer cells or promotes 
tumour growth [102]. To summarise, these results demonstrate the validity of our 
approach to isolate and analyse CAS and normal stroma from FFPE subsections by 
RNAseq, and reveal several interesting changes between normal and tumour stroma 
in canine mammary carcinomas. 
 
7.3.3 Validation of selected human CAS markers in canine mammary 
carcinoma 
The new dataset contained data for 8 of the 9 stromal markers analysed in a previous 
study [75, 76]. All 8 genes (ACTA2, COL1A1, FAP, MMP2, CXCL12, CAV1, 
PDGFRB, IL6) were significantly deregulated when comparing normal stroma and 
CAS (Figure 6). ACTA2, COL1A1 and FAP were up-regulated in both datasets which 
is consistent with findings in human studies. A detailed overview and discussion 
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regarding the known involvement of all these markers in tumour biology and the 
interpretation of their expression changes can be found in my master thesis as well 
as our paper [75, 76].  
Differences regarding deregulation of genes detected by the RNAseq results 
compared to our previous study may be due to the smaller sample size in the 
previous study, and the different analysis method (RT-qPCR vs. RNAseq). Especially 
in some cases, such as for IL6, expression could only be detected in a small subset 
of analysed cases in the old dataset, which strongly limited the statistical power. Also, 
normalisation strategies differ strongly between RT-qPCR and RNAseq, which can 
influence detection of gene expression changes. To conclude, by comparing two 
independent datasets generated by two different methods, we validated deregulation 
of ACTA2, COL1A1, FAP and, CXCL12 in canine CAS. Furthermore, our results 
suggest a significant contribution of MMP2, CAV1, PDGFRB and IL6 gene 
expression changes in the biology of canine mammary tumours. 
 
7.3.4 Changes in stromal gene expression during tumour progression in 
canine mammary carcinomas 
Our results revealed significant changes in gene expression comparing CAS of 
metastatic and non-metastatic canine mammary tumours (Figure 7). Again, no clear 
difference of the gene expression pattern between the different histological grades 
could be seen comparing the two conditions (metastatic, non-metastatic). Therefore, 
these results further support the demand for more accurate prognostic indicators in 
cancer diagnostics besides histological and clinical criteria [48]. 
Hierarchical clustering of significantly deregulated genes showed a similar gene 
expression pattern among the normal stroma samples of metastatic and non-
metastatic tumours. This demonstrates the similar behaviour of normal stroma in both 
tumour types and validates proper isolation of normal stroma, also because gene 
expression clearly differs between normal stroma and CAS (Figures 3 and 7). In 
contrast, clear difference could be detected comparing CAS samples of metastatic 
and non-metastatic tumours with greatest differences in clusters 3, 4, 5 and 6 (Figure 
7). These clusters contain genes affecting cell differentiation, cell adhesion and 
angiogenesis, biological processes known to be altered in tumour tissues and also 
associated with the induction of EMT, an important mechanism needed for cancer 
cells to form metastasis [8, 9, 11, 15] (Figure 8). Furthermore, processes involved in 
bone remodelling including the negative regulation of osteoblast differentiation seem 
to be regulated differently in CAS of metastatic tumours. Suppression of osteoblast 
activity through cancer cells was associated with bone metastasis in human breast 
cancer [103, 104]. Another main process to be affected in the metastatic CAS is the 
immune response. Negative chemotaxis of leucocytes and mononuclear cells like 
lymphocytes leading to an immunosuppressive microenvironment is often induced by 
CAFs or IICs themselves and is associated with metastasis and worse prognosis [8, 
9]. Pathway analysis of the up- and down-regulated genes in CAS of metastatic 
tumours exhibited similar categories as gene ontology analysis, and could mostly be 
grouped into five interesting clusters (Figure 9). The up-regulated genes were mainly 
involved in chemotaxis, immune response and regulation of apoptosis. Pathways 
overrepresented among the down-regulated genes showed involvement in immune 
response, GnRH signalling and TGFβ signalling. The most interesting genes were 
divided into seven groups of which four were further analysed in detail (Table 4). 
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The first group exhibited genes involved in TGFβ signalling pathway, known to play a 
role in cell differentiation, growth, migration and tumorigenesis including 
angiogenesis, EMT, and immunosuppression [8, 9, 11, 12, 14, 21, 105]. The pathway 
is induced by binding of TGFβ to two cell surface receptor kinases (TGFBR1, 
TGFBR2) and followed by phosphorylation of Smad proteins which activate specific 
gene transcription [105]. TGFβ is expressed by various stromal cells including CAFs, 
ACVs and IICs, emphasising the contribution of CAS to this pathway [7, 9, 11, 12, 14, 
21]. In our dataset, genes significantly associated with TGFβ signalling include DIO3, 
TGFB2, TGFBR3 and LTBP4 (Table 4). DIO3, up-regulated in metastatic CAS, is a 
deiodinase inactivating thyroid hormones which are important for development, cell 
differentiation and maintenance of proper metabolism in cells. DIO3 was shown to be 
expressed in fibroblast under stimulation of TGFβ and activated in adults promoting 
growth in solid tumours. The effect may be due to local hypothyreodism induced by 
DIO3 which results in enhanced cell proliferation and inhibition of cell differentiation 
[105]. TGFB2 and TGFBR3 are directly involved in the TGFβ signalling pathway. 
TGFB2 encodes a protein involved in forming TGFβ, thus activating the TGFβ 
signalling cascade. We found TGFB2 up-regulated in CAS compared to normal 
stroma but down-regulated in CAS of metastatic tumours when compared to non-
metastatic tumours, thus either indicating minor involvement in the formation of 
metastasis, or the importance of dampening TGFB2 signalling during tumour 
progression. TGFβ was also described to be down-regulated in stromal cells when 
co-cultured with metastatic tumour cells [106]. Some studies also suggest TGFβ to 
function as a tumour suppressor. A study in canine mammary tumours found the 
down-regulation of various growth factors, including their receptors like TGFBR2 or 
TGFBR3, in metastatic tumours when comparing with normal tissue [62]. TGFBR3 
has also been shown to be down-regulated in our dataset, and decreased expression 
was observed in various cancers associated with poor outcome [107-109]. LTBP4, 
down-regulated in our dataset, is a TGFβ binding protein, and its down-regulation in 
canine mammary tumours was associated with malignancy [110, 152]. 
 
The second group contains genes involved in HIF-1 signalling a pathway which is 
activated under hypoxic condition by HIF-1 and often found in advanced solid 
tumours. Activation of the HIF-1 signalling pathway drives transcription of various 
genes and gets modulated to promote survival of hypoxic cells [105]. DIO3, TGFB2, 
STC2, WT1, and RHOBTB3 (Table 4) are significantly deregulated genes of our 
dataset associated with HIF-1 signalling [105, 111-113]. DIO3 has been shown to be 
induced under hypoxic conditions and to decrease the metabolic rate and oxygen 
consumption by inhibition of T3 (active form of thyroid hormone) [105]. RHOBTB3 is 
a Rho GTPase which has been shown to be involved in tumorigenesis. It suppresses 
the Warburg effect and deregulates the assembly of the HIFα complex, thus down-
regulation as seen in our data is suggested to promote HIF-1 signalling [111, 114, 
115]. WT1 encodes the transcription factor wilms tumor 1 which plays an important 
role in normal development. Contradicting results regarding expression of WT1 for 
breast cancer progression are found in literature [113, 116, 117]. Moreover, STC2 
encoding a glycoprotein hormone and representing a HIF-1 target gene, has been 
suggested to play a role in tumour development by inhibiting tumorigenesis, 
metastasis and EMT of breast cancer cells. Therefore, down-regulation as seen in 
our dataset can promote tumour progression [112, 118]. 
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Another main category altered in metastatic CAS was the immune response. Our 
data exhibits up-regulated genes like GIMAP8, BIN2, HLA-DRB1, and FASLG to be 
involved in this process (Table 4). GIMAP8 is a GTPase IMAP family member whose 
function is still not fully understood. It has been shown to be overexpressed in CAS 
and has been suggested to play a role in T-cell apoptosis, thus promoting an immune 
suppressive microenvironment [119-122]. BIN2 has been suggested to play a role in 
leucocyte motility and phagocytosis [123]. HLA-DRB1 belongs to the MHC II 
molecule complex expressed in antigen presenting cells like dendritic cells or 
macrophages. However, the gene has been shown to be associated with worse 
prognosis in human cancer patients when down-regulated or did not show significant 
association with prognosis [124, 125]. FASLG encodes a ligand which is a member of 
the TNF superfamily and induces apoptosis by binding FAS. It is known to play a role 
in immune system regulation including induction of T-cells apoptosis and has been 
suggested to be involved in tumour progression [126, 127]. Therefore, literature 
supports our findings of FASLG up-regulation in CAS of metastatic tumours. 
 
The last group included genes like MMP11 and OLFML2B which were up-regulated 
in metastatic CAS and genes such as FN1, VIT, and COL14A1, which were down-
regulated in metastatic CAS. All of these genes are involved in ECM remodelling, a 
process which involves genes that have been shown to be among the most 
deregulated genes in CAS [16]. ECM remodelling is regarded as an important step 
for tumour progression and metastasis [8, 14, 15]. MMP11 is a matrix 
metalloproteinase which, in contrast to other MMPs, has no direct influence on ECM 
degradation but cleaves enzymes like proteinase inhibitors [128, 129]. However, one 
study shows the involvement of MMP11 in collagen VI degradation, a constituent of 
the ECM surrounding adipocytes [130]. Expression of MMP 11 in stromal cells has 
been shown to be associated with higher risk of invasive tumour growth and 
metastasis and has been suggested as prognostic factor, as it correlates with worse 
clinical outcome in patients with invasive breast cancer [128, 129, 131, 132]. Up-
regulation of MMP11 has also been found during progression from in situ to invasive 
breast cancer [133]. Moreover, an analysis of whole canine mammary tumours found 
up-regulation of MMP11 in metastatic tumours compared to non-metastatic tumours 
[61] . OLFML2B is a gene encoding an olfactomedin domain-containing protein, 
which represents a secreted glycoprotein [134]. Olfactomedins play an important role 
in neurogenesis, cell adhesion, cell cycle regulation, and tumorigenesis. Proteins 
encoded by OLFML2B have been shown to bind chondroitin sulphate-E and heparin 
in the ECM. Nevertheless, the function of OLFML2B is still not clear even though our 
dataset suggests an involvement of this gene in canine mammary tumour 
progression [134, 135]. FN1 encodes fibronectin, a glycoprotein and constituent of 
the ECM that is secreted by CAFs and involved in wound healing, fibrosis, 
lymphangiogenesis, proliferation and migration, and has been associated with drug 
resistance of cancer cells [8, 9, 12, 14, 16]. In our dataset FN1 was up-regulated 
comparing CAS over normal stroma, but lower in CAS of metastatic than non-
metastatic tumours. This may suggest a minor role of FN1 in tumour progression of 
canine mammary tumours. VIT is a gene encoding vitrin, an ECM protein which may 
be associated with cell adhesion, matrix assembly and migration [136, 137]. In 
cartilage tissue vitrin has been shown to be down-regulated in the ECM surrounding 
hypertrophic chondrocytes, whereas high expression was detected in the ECM 
surrounding pre-hypertrophic chondrocytes [137]. As VIT was lower in metastatic 
CAS in our dataset, its downregulation may also play a role in tumour progression. 
COL14A1 encodes the alpha chain of type XIV collagen and is a large glycoprotein of 
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the ECM. It interacts with collagen fibrils, is involved in fibrillogenesis, and has been 
revealed to be frequently absent close to invasive tumours [138]. Moreover, 
COL14A1 has been shown to be mutated and down-regulated in triple-negative 
breast cancer patients, a molecular breast cancer subtype which exhibits the worst 
prognosis [139]. Therefore, similar deregulation of COL14A1 in CAS of metastatic 
tumours observed in our canine dataset, may suggest the same function of this gene 
as in human breast cancer patients. 
 
7.3.5 Validation of RNAseq results by RT-qPCR 
Validation of data obtained by RNA sequencing was performed by RT-qPCR for 7 
genes (Figure 11). The expression trends of all genes analysed closely matched the 
sequencing results. However, comparing all conditions with each other, significant 
difference between CAS of the metastatic and non-metastatic samples was only 
detected for MMP11 (Figure 11A). It was highly up-regulated in CAS of metastatic 
tumours compared to all three other conditions. This is in line with literature regarding 
its supportive role in tumour progression in both human and canine mammary 
carcinoma [61, 128, 129, 131-133]. This further confirms that ECM remodelling is an 
important process affected during tumour progression, and MMP11 may be 
suggested as a biomarker for metastasis in canine mammary tumours. To further 
verify its contribution to tumour progression a more detailed analysis of the gene is 
needed.  
For VIT, TGFBR3 and PCOLCE2 the gene expression declined from normal stroma 
of non-metastatic tumours to normal stroma of metastatic tumours followed by CAS 
of non-metastatic tumours and showing the lowest expression levels in CAS of 
metastatic tumours. Indicating that down-regulation of these genes may promote 
metastasis in canine mammary tumours. However, these findings have to be further 
validated using more samples. The same applies for SFRP1 and DIO3 (Figures 11F 
and G). The lack of significance for some of the genes may be due to a small sample 
number included in the qPCR analysis and the different normalisation strategy used, 
with 3 housekeeping genes that were analysed. 
As expected no significant differences could be detected comparing normal stroma of 
metastatic and non-metastatic samples. However, a declining tendency could be 
observed suggesting normal stroma of metastatic tumours may already show some 
alterations compared to normal stroma of non-metastatic tumours. Therefore, for 
future studies a larger distance for isolation of normal stroma may be considered to 
uncover even more deregulated genes. On the other hand, hierarchical clustering of 
the comparison from stroma of metastatic over non-metastatic samples showed a 
similar expression pattern for both normal stroma of metastatic and normal stroma of 
no-metastatic samples, which suggests validity of the isolation approach. 
 
7.3.6 CAS markers of metastatic canine mammary carcinomas associated with 
survival in human breast cancer 
To see whether gene expression changes in metastatic canine CAS could also 
predict worse prognosis in human breast cancer, we analysed whether the 
expression of the identified markers for metastatic canine CAS was associated with 
survival in a human breast cancer dataset derived from whole tumour sequencing. 
Indeed, a significant association with survival was displayed for TGFB2, VIT, 
COL14A1, SLIT2, and SEMA3G (Figure 12). COL14A1 and TGFB2 have already 
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been described to be associated with prognosis in breast cancer patients, the latter 
showing better prognosis when up-regulated in patients without metastasis in the 
lymph node [139, 140]. SLIT2 encodes a glycoprotein secreted by CAFs which is 
involved in cell migration and which is associated with metastasis and worse 
prognosis when down-regulated [141-144]. SEMA3G is a gene encoding a protein 
involved in angiogenesis and tumour progression supporting tumour cell invasion and 
has been associated with longer survival when up-regulated [145-147]. More 
significant associations of stromal genes with survival may be found if a different 
dataset for comparison was used. The TCGA dataset checked by the TIMER 
software contains data of the whole tumour tissue, therefore presenting a mix of 
stromal and tumour cell gene expression signatures. As a consequence, the gene 
expression pattern of tumour cells could possibly overlap the gene expression 
signature of stromal cells. For example in case of the membrane protein CD36, 
worse prognosis has either been shown to be associated with CD36 down-regulation 
in stromal cells or has been shown to be associated with up-regulation of CD36 in 
cancer cells [148-151]. As MMP11 was shown to be a potential biomarker detected in 
CAS of metastatic mammary tumours, an association with survival would be 
expected. However, no significant association of MMP11 with survival was found 
using the TIMER software. Nevertheless, literature shows significant association of 
MMP11 with shorter relapse-free and overall survival in breast cancer patients [129, 
132]. Taken together, these results display the usefulness of the comparison of CAS 
from canine and human mammary carcinomas regarding the identification of genes 
possibly involved in tumour progression and worse prognosis. 
 
7.4 Conclusion/Outlook 
To conclude, our findings demonstrate that CAS in canine mammary tumours 
undergoes strong reprogramming mechanisms, which are largely comparable with 
data from human breast cancer and which supports the use of the dog as a 
representative model for human breast cancer. More precisely, genes involved in 
ECM remodelling, immune response, angiogenesis, coagulation, EMT, metabolism 
and signalling pathways including TGFβ- or HIF-1 signalling seem to play an 
important role during tumour progression in both canine and human mammary 
carcinomas. In particular MMP11 has been shown to be significantly up-regulated in 
CAS of metastatic canine mammary carcinomas by RNAseq and validation with 
qPCR, suggesting MMP11 as a possible new biomarker in canine mammary 
carcinomas. To further support these results and to find even more interesting 
deregulated targets, a more detailed analysis of the data will be the subject of follow-
up projects in the lab. These may lead to the discovery and development of new 
diagnostic and therapeutic targets for canine and human breast cancer. 
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